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Zusammenfassung 
Streptococcus pneumoniae ist die häufigste Ursache für ambulant erworbene Pneumonien 
weltweit. Daher müssen die Wirts-Pathogen-Interaktionen erforscht werden, um neue 
Therapiestrategien zu entwickeln. In dieser Studie habe ich 1. den Typ I Interferon (IFN)-
stimulierenden Signalweg des angeborenen Immunsystems in Pneumokokken-infizierten 
Wirtszellen sowie 2. dessen Bedeutung in der Pneumokokkenpneumonie untersucht. 
Humane und murine Makrophagen, aber nicht alveolare Epithelzellen, produzierten Typ I 
IFNs nach Infektion mit S. pneumoniae. Dieses war abhängig vom Virulenzfaktor 
Pneumolysin und erforderte sowohl die Phagozytose der Bakterien als auch die Ansäuerung 
der Endosomen. Die Induktion der Typ I IFNs wird durch einen zytosolischen Signalweg 
vermittelt, welcher wahrscheinlich DNA erkennt und sowohl das Adapterprotein STING als 
auch den Transkriptionsfaktor IRF3 aktiviert. 
Typ I IFNs, welche von infizierten Makrophagen gebildet wurden, regulierten die Expression 
von IFN-stimulierten Genen (ISGs) und Chemokinen in Makrophagen und co-kultivierten 
alveolaren Epithelzellen in vitro und in Mauslungen in vivo. In einem murinen 
Pneumoniemodell hatten die Typ I IFNs jedoch einen negativen Effekt für den Wirt. Mäuse 
mit einem Defekt im Typ I IFN-Rezeptor oder mit einem Knockout im Typ I und Typ II IFN-
Rezeptor hatten eine signifikant geringere Bakterienlast in der Lunge und eine verminderte 
Reduktion der Körpertemperatur und des Körpergewichtes als wild-typ Mäuse. Diese Effekte 
waren nicht durch Änderungen in der Zellrekrutierung oder durch Änderungen der Zytokin-
/Chemokinexpression erklärbar. 
Zusammenfassend lässt sich feststellen, dass Typ I IFNs durch Pneumokokken induziert 
werden, aber dass sie trotz einiger positiver Effekte auf die Expression von ISGs einen 
negativen Gesamteffekt in einem murinen Pneumoniemodell aufweisen. Ein detailliertes 
Verständnis der Typ I IFN-Antwort während der Pneumokokkeninfektion kann die 
Entwicklung neuer Therapiestrategien unterstützen. 
Schlagwörter: Streptococcus pneumoniae, Typ I Interferone, DNA, Pneumonie 
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Summary 
Streptococcus pneumoniae is the leading cause of community-acquired pneumonia world-
wide. A detailed understanding of the host-pathogen interactions is required in order to foster 
the development of new therapeutic strategies. Here, I (I) characterized an innate immune 
recognition pathway that senses pneumococcal infection and triggers the production of type I 
interferons (IFNs), and (II) examined the role of type I IFNs in pneumococcal pneumonia in 
mice. 
Human and murine macrophages, but not alveolar epithelial cells, produced type I IFNs after 
infection with S. pneumoniae. This induction was dependent on the virulence factor 
pneumolysin, the phagocytosis of the bacteria, and the acidification of the endosome. 
Moreover, it appeared to be mediated by a cytosolic DNA-sensing pathway involving the 
adaptor molecule STING and the transcription factor IRF3. 
Type I IFNs produced by S. pneumoniae-infected macrophages positively regulated the 
expression of IFN-stimulated genes (ISGs) and chemokines in macrophages and co-cultured 
alveolar epithelial cells in vitro and in mouse lungs in vivo. However, in a murine model of 
pneumococcal pneumonia, type I IFN signaling was detrimental to the host defense. Mice 
deficient in the type I IFN signaling or double deficient in type I and type II IFN signaling had 
a significantly reduced bacterial load in the lung and a diminished reduction of body 
temperature and body weight compared to wild-type mice. The decreased susceptibility of 
the knockout mice was unlikely to be attributable to alterations in cell recruitment or 
cytokine/chemokine production. 
In conclusion, type I IFNs are induced during pneumococcal infection. However, despite their 
positive effects on the expression of some ISGs and chemokines, they negatively affect the 
outcome of pneumococcal pneumonia in an in vivo mouse model. Targeting the type I IFN 
system could potentially be an effective way in enhancing the immune response in patients 
with S. pneumoniae pneumonia. 
Keywords: Streptococcus pneumoniae, type I interferons, DNA, pneumonia 
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Tab. 1:  List of abbreviations 
AIM2 absent in melanoma 2 
APC antigen-presenting cell 
ASC apoptosis-associated speck-like protein containing CARD 
BAL broncho-alveolar lavage 
BMM bone marrov-derived macrophage 
B6 C57BL/6 
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CD cluster of differentiation 
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DMEM Dulbecco’s Modified Eagle Medium 
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DNA deoxyribonucleic acid 
dsRNA double-stranded RNA 
EDTA ethylenediaminetetraacetic acid 
ELISA enzyme-linked immunosorbent assay 
FACS fluorescence activated cell sorting 
FCS fetal calf serum 
Fig. Figure 
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F. tularensis Francisella tularensis 
GAF gamma-interferon activation factor 
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GAPDH glyceraldehydes-3-phosphate dehydrogenase 
GAS gamma interferon activation site 
GM-CSF granulocyte macrophage colony-stimulating factor 
GpIIA-PLA2 Group IIA phospholipase A2 
HBSS Hank’s Balanced Salt Solution 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIN200 hematopoietic interferon-inducible nuclear antigens with 200 
amino acid repeats 
HIV  human immunodeficiency virus 
IFI16 interferon, gamma-inducible protein 16 
IFN interferon 
IFNAR interferon α/β receptor 
IFNGR interferon γ receptor 
IFNα/β type I IFN 
IL interleukin 
IgG, IgM immunoglobulin G, immunoglobulin M 
iNKT cell invariant natural killer T cell 
IPD invasive pneumococcal disease 
IRAK IL-1R-associated kinase 
IRF interferon-regulatory factor 
IRG immunity-related GTPase 
ISG interferon-stimulated gene 
ISGF3 interferon-stimulated gene factor 3 
ISRE interferon-stimulated response element 
JAK janus kinase 
KC CXCL1 chemokine 
L. pneumophila Legionella pneumophila 
L. monocytogenes Listeria monocytogenes 
LPS lipopolysaccharide 
LRRFIP-1 leucine rich repeat (in FLII) interacting protein 1 
LRT lower respiratory tract 
Mal MyD88 adaptor-like 
MALP2 macrophage-activating lipopeptide 
MAP kinases mitogen-activated protein kinases 
MAVS mitochondrial antiviral-signaling protein 
MBL mannan-binding lectin 
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MCP-1 monocytes chemotactic protein-1 
MCS-F macrophage colony-stimulating factor 
MDA5 melanoma differentiation-associated gene 5 
mDC myeloid dendritic cell 
MDP muramyl dipeptide 
MHC major histocompatibility complex 
MIP-2 macrophage inflammatory protein 2 
mM millimolar 
MOI multiplicity of infection 
mRNA messenger RNA 
Mx protein myxovirus (influenza virus) resistance protein 
MyD88 myeloid differentiation primary response gene 88, which also 
mediates IL-1 receptor and IL-18 receptor signaling 
M. tuberculosis Mycobacterium tuberculosis 
NET neutrophil extracellular trap 
NF-κB nuclear factor-κB 
NLR NOD-like receptor 
NLRP3 NOD-like receptor family, pyrin domain containing 3 
NOD nucleotide-binding oligomerization domain-containing protein 
n.s. not significant 
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell 
PBS phosphate-buffered saline 
pDC plasmacytoid dendritic cell 
Pen/Strep Penicillin/Streptomycin 
p.i. post infection 
PLY pneumolysin 
PMN polymorphonuclear leukocytes 
poly dA:dT poly(deoxyadenylic:deoxythymidylic) acid 
poly dG:dC poly(deoxyguanylic:deoxycytidylic) acid 
poly I:C poly(inosinic:cytidylic) acid 
PRR pattern recognition receptor 
PYHIN pyrin and HIN200 domain–containing proteins 
p300 E1A binding protein p300 
PKR double-stranded RNA-dependent protein kinase 
RANTES regulated upon activation, normal T cell expressed and 
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presumably secreted 
RIG-I retinoic acid-inducible gene I 
RIP2 receptor-interacting protein 2 
RLR RIG-I-like receptor 
RNA ribonucleic acid 
RNAi RNA interference 
ROS reactive oxygen species 
siRNA small interfering RNA 
ssRNA single-stranded RNA 
STAT signal transducer and activator of transcription 
STING stimulator of IFN genes 
S. pneumoniae Streptococcus pneumoniae 
S. typhimurium Salmonella typhimurium 
Tab. Table 
TAMRA 5-carboxytetramethylrhodamine 
THY Todd-Hewitt broth + yeast extract 
TLR toll-like receptor 
TNFα tumor necrosis factor α 
TRAM TRIF-related adaptor molecule 
TRIF TIR domain-containing adaptor inducing IFNβ 
URT upper respiratory tract 
ZBP-1 Z-DNA-binding protein 1 
6-FAM 6-Carboxyfluorescein 
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1. Introduction 
1.1 Streptococcus pneumoniae 
1.1.1 Biology 
Streptococcus pneumoniae, also known as “the pneumococcus”, is a gram-positive 
bacterium that frequently colonizes the upper respiratory tract (URT) of humans but can also 
cause invasive pneumococcal disease (IPD) (Lynch and Zhanel, 2010). Its genome contains 
approximately 2.1 million base pairs that encode an approximate number of around 1880 
genes. These include 1553 genes essential for the viability, 154 genes required for virulence, 
and 176 genes that can actively maintain a non-invasive phenotype (van der Poll and Opal, 
2009). Pneumococci are surrounded by a polysaccharide capsule that determines their 
serotype. To this date, more than 90 different serotypes of S. pneumoniae are known 
(Kadioglu, et al., 2008). 
On their surface, pneumococci express a diverse array of transporters that mediate the in- 
and export of substrates and proteins, but that also play a role in acquiring genetic 
competence and resistance to antibiotics (van der Poll and Opal, 2009). Other surface 
proteins are involved in the adhesion of S. pneumoniae to epithelial surfaces, tissue invasion, 
and interference with the immune response of the host (Beiter, et al., 2006; Mitchell and 
Mitchell, 2010). 
The pneumococcal capsule itself is an important virulence factor. It is covalently attached to 
peptidoglycans of the outer cell wall of S. pneumoniae. It has a thickness of approximately 
200-400 nm. The surface of the capsule carries a high negative charge that electrostatically 
repulses the sialic acid moieties in the host mucus and prevents the mechanical clearance 
from the nasopharynx (Kadioglu, et al., 2008; Nelson, et al., 2007). The capsule also protects 
S. pneumoniae against the immune response of the host by impairing pneumococcal 
opsonization with complement factors, immunoglobulins, and the C-reactive protein, as well 
as by inhibiting phagocytosis and killing by neutrophils (Hyams, et al., 2010). During the early 
phase of colonization, pneumococci tend to express thin capsules in order to permit contact 
between the bacteria and the epithelial surfaces. In invasive disease, however, thicker 
capsules are required so that S. pneumoniae can evade phagocytosis and other immune 
defense mechanisms (van der Poll and Opal, 2009). 
Pneumolysin (PLY), a 53 kDa pore-forming toxin, is another critical virulence factor of S. 
pneumoniae. It is produced by almost all clinical isolates. After the release of PLY from the 
bacterium, it binds to the cholesterol in the host membrane, where it oligomerizes in order to 
form large pores of up to 30 nm in diameter (Mitchell and Mitchell, 2010; van der Poll and 
Opal, 2009). High amounts of PLY lead to the lysis of the host cells, but it also has biological 
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effects at sub-lytic concentrations. These include inhibition of the cilliary action of epithelial 
cells, impairment of the respiratory burst of phagocytic cells, as well as activation of the 
complement system and cytokine/chemokine production (Hirst, et al., 2008; Maus, et al., 
2004; Rubins, et al., 1996; Witzenrath, et al., 2006). Pneumococcal strains deficient for PLY 
tend to display reduced levels of virulence and induce less inflammation and neutrophil 
recruitment. Moreover, functional PLY was implicated to be required for the pneumococcal 
survival in the upper and lower respiratory tract as well as for the invasion into the blood 
stream (Hirst, et al., 2008; Kadioglu, et al., 2002; Wellmer, et al., 2002). However, serotype 1 
and 8 strains carrying a non-cytolytic PLY were still isolated from cases of invasive disease. 
It is possible, that expression of this non-cytolytic PLY might represent an immune evasion 
strategy for these pneumococcal strains (Kadioglu, et al., 2008; Witzenrath, et al., 2011). 
1.1.2 Epidemiology and disease 
Streptococcus pneumoniae is the main cause of community-acquired pneumonia world-wide, 
but can also lead to meningitis, otitis media, and sepsis. Approximately 10% of adults, 20-
40% of healthy children, and >60% of infants and children in daycare are colonized by 
pneumococci. This colonization can either be asymptomatic and disappear after a while or it 
can progress to invasive disease (van der Poll and Opal, 2009). An estimated 1.6 million 
people per year die of IPD world-wide, the majority of which are children below the age of 5 
years (Lynch and Zhanel, 2010; Parsons and Dockrell, 2002; WHO, 2008). Risk factors 
include age <2 years and >65 years, a compromised immune system (HIV, asplenia, organ 
transplant recipients), poverty, restricted access to healthcare, and co-morbidities (e.g. 
influenza infection) (O'Brien, et al., 2009; Parsons and Dockrell, 2002). Vaccines targeting 
several pathogenic pneumococcal serotypes result in a serotype-specific decrease of IPD 
and reduce the likelihood of transmission. However, non-vaccine strains can outcompete the 
targeted strains. This is thus raising the possibility for new serotypes to colonize the URT 
(Frazao, et al., 2010). 
After encountering the host, S. pneumoniae colonizes the nasopharynx and competes with 
other commensals for this niche (Lysenko, et al., 2010). Pneumococcal carriage induces the 
systemic and mucosal production of strain- and serotype-specific IgG antibodies, which are, 
however, not sufficient for bacterial clearance (Richards, et al., 2010; Simell, et al., 2009). 
The pneumococci are either cleared after several weeks to months or can progress to IPD. A 
study showed that low-invasive serotypes have a longer duration of colonization than 
invasive serotypes (Sleeman, et al., 2006). At the epithelium, the expression of the capsule is 
down-regulated and adherence factors are exposed on the surface of the pneumococcus. 
These factors interact with host proteins, for example with the receptor for the platelet-
activating factor, which allows invasion of the pneumococci into the epithelium and into the 
tissue (Gould and Weiser, 2002; Thornton, et al., 2010). Moreover, the immune response of 
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the host against commensal bacteria in the nasopharynx contributes to the weakening of the 
epithelial barrier and facilitates bacterial invasion (Clarke, et al., 2011). By progressing from 
the nasopharynx to the lower respiratory tract or by migrating through the epithelial barrier 
pneumococci gain access to sterile compartments, such as lung, brain, middle ear, and 
blood, where they cause disease. To this date the mortality rate in adults remains at 10-30% 
for bacteremic pneumonia and 16-37% for meningitis. This indicates a strong need for new 
therapeutic strategies (Lynch and Zhanel, 2010). 
1.2 The immune system 
1.2.1 The innate immune system 
The innate immune system is the first-line defense of a host against pathogens. It is 
immediately activated by germline-encoded receptors after detection of microbial invasion or 
tissue damage. This results in the production of pro-inflammatory cytokines, the subsequent 
recruitment of phago- and lymphocytes, and in the initiation of the adaptive immune 
response. Thus, the innate immune system is important for starting and shaping the immune 
response of the host. (Medzhitov and Janeway, 2000). 
The innate immune response can be initiated by basically every cell type which comes in 
contact with microbes, microbial molecules or endogenous danger signals (see below). The 
specific cell type responsible depends on the type of pathogen and the type of infection. In 
bacterial lung infections, for example, resident macrophages might be most important for the 
initiation, while other cell types including dendritic cells (DCs) and epithelial cells contribute to 
this response. Receptors (see below) on the plasma membrane, in the endosomes, or in the 
cytosol of these cells then sense conserved structures of the pathogen, the “pathogen-
associated molecular patterns” (PAMPs) (Chaplin, 2010; Vance, et al., 2009). After sensing 
PAMPs, the cells produce cytokines and chemokines in order to activate neighboring cells 
and to attract neutrophils and exudate macrophages. The recruited cells help to eliminate the 
invading pathogens through phagocytosis, secretion of antimicrobial peptides, production of 
reactive oxygen species/nitrogen intermediates, and formation of neutrophil extracellular 
traps (Papayannopoulos and Zychlinsky, 2009). The DCs migrate to the peripheral lymph 
nodes, where they directly stimulate T- and indirectly B-lymphocytes and initiate the adaptive 
immune response (Chaplin, 2010; Ryu, et al., 2010). 
Another part of the innate immunity is the complement system (Skattum, et al., 2011). 
Soluble factors in the serum such as antibodies or lectins (e.g. mannan-binding lectin) 
adhere to structures on the surface of pathogens. After binding, they initiate the complement 
cascade and induce the lysis and/or the phagocytosis of the microbes. 
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A great variety of cytokines and chemokines are produced during the innate immune 
response that maintain, shape, and in the end terminate the defense mechanisms. The 
coordinated functions of the cyto-/chemokines determine the type of the following immune 
response. 
1.2.2 Pattern recognition receptors 
The innate immune response is stimulated by the activation of pattern-recognition receptors 
(PRRs). PRRs are present on the plasma membrane, in the endosomes, or in the cytosol. 
They sense conserved structures that can be either derived from microbial pathogens 
(pathogen-associated molecular patterns – PAMPs) (Janeway, 1989) or from damaged host 
cells and tissues (danger-associated molecular patterns – DAMPs) (Matzinger, 1994). 
PAMPs are structures that are present in a broad range of pathogens (such as cell wall 
components or microbial nucleic acids) and are essential for their survival and replication. 
This ensures that a limited number of germline-encoded receptors can detect a limited 
amount of conserved structures and still be effective against a broad range of microbes. 
DAMPs are endogenous intracellular molecules that are released upon cellular damage and 
activate PRRs. They generally indicate damage inside the organism without the requirement 
of a preceding infection; although their role in infections becomes increasingly recognized 
(Horvath, et al., 2011). 
1.2.2.1 Toll-like receptors 
Toll-like receptors (TLRs) are conserved in vertebrates, insects, and nematodes and are 
composed of 10 members in humans and 12 members in mice. They can either be localized 
on the plasma membrane (TLR1, -2, -4, -5, -6) or in the endosomal compartment (TLR3, -7, -
8, -9). TLR4 can relocate from the plasma membrane to the endosomes after stimulation 
(O'Neill and Bowie, 2007). TLRs are composed of an extracellular ligand-binding domain and 
an intracellular signaling domain. Upon ligand binding, the TLRs homo- or heterodimerize 
and activate downstream signaling pathways. Most TLRs are known to homodimerize, but 
e.g. TLR2 can form heterodimers with either TLR1 or TLR6. Bacterial cell wall components, 
such as peptidoglycans are sensed by TLR2 homodimers (Schroder, et al., 2003).The TLR2 
heterodimers TLR1/2 and TLR2/6 are able to recognize tri- and diacetylated lipopeptides, 
respectively (Takeda, et al., 2002; Takeuchi, et al., 2002). TLR4 senses lipopolysaccharide 
(LPS) of gram-negative bacteria (Poltorak, et al., 1998) and is also discussed to recognize 
pneumococcal PLY (Malley, et al., 2003). TLR5 is activated by flagellin (Hayashi, et al., 
2001). The endosomal TLRs are activated by nucleic acids, such as single-stranded RNA 
(TLR-7, -8) (Heil, et al., 2004), double-stranded RNA (TLR3) (Alexopoulou, et al., 2001), or 
unmethylated CpG motifs in double-stranded DNA (TLR9) (Hemmi, et al., 2000).  
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The stimulation of TLRs induces the recruitment of adaptor molecules (MyD88, Mal, TRIF, 
TRAM), which subsequently initiate pro-inflammatory signaling cascades. MyD88 is a central 
adaptor molecule for all TLRs (except TLR3) and is also recruited to the IL-1 receptor. It 
mediates the formation of a signaling complex that activates the transcription factor NF-κB as 
well as MAP kinases and leads to the production of cytokines and chemokines (O'Neill and 
Bowie, 2007). Children deficient in MyD88 or a component of its signaling complex (IRAK4) 
suffer from recurrent cases of IPD (Picard, et al., 2010). Mal is a supporting adaptor for 
MyD88-dependent signaling that acts as a connecter between TLR2 or -4 and MyD88. TRIF 
is the adaptor molecule for TLR3 and TLR4 and activates NF-κB as well as the IRF3 
transcription factor, which leads to the production of type I interferons (IFNs). Type I IFNs are 
important in antiviral and antibacterial defenses (see below). Mice deficient in TRIF had an 
impaired immune response to lung infections of the gram-negative bacteria Klebsiella 
pneumoniae and Escherichia Coli characterized by diminished cytokine/chemokine 
production and neutrophil recruitment (Cai, et al., 2009; Jeyaseelan, et al., 2007). Moreover, 
TRIF-/- mice infected with Klebsiella pneumoniae had a decreased survival and bacterial 
clearance (Cai, et al., 2009). TRAM is the fourth adaptor molecule of the TLRs and connects 
TLR4 to TRIF thus allowing TLR4 to activate IRF transcription factors (O'Neill and Bowie, 
2007). Thus, activation of TLR4 on the cell surface triggers an early response of NF-κB 
activation via MyD88 and MAL, whereas in the late phase TLR4 shuttles to the endosome 
and activates NF-κB and IRF transcription factors via the adaptors TRAM and TRIF 
(Palsson-McDermott and O'Neill, 2004). 
1.2.2.2 NOD-like receptors 
NOD-like receptors (NLRs) are cytosolic PRRs that can be functionally divided into two 
groups: one group is activating pro-inflammatory signaling pathways leading to the 
stimulation of NF-κB and MAP kinases, whereas the other group is forming inflammasomes 
(Chen, et al., 2009). Inflammasomes are multi-protein complexes that activate caspase-1, 
which subsequently cleaves the cytokines pro-IL-1β and pro-IL-18 into their mature and 
active forms (Schroder and Tschopp, 2010). 
NOD1 and NOD2 belong to the group of NLRs that activate NF-κB and MAP kinase 
pathways. NOD1 senses muropeptides of gram-negative and some gram-positive bacteria, 
whereas NOD2 detects muramyl dipeptides of both gram-negative and gram-positive 
bacteria (Chen, et al., 2009). Stimulation of these NLRs leads to the phosphorylation of the 
RIP2 kinase and to the subsequent activation of NF-κB and MAP kinases. This results in the 
production of pro-inflammatory cytokines. Additionally to activating the above mentioned 
pathways, NOD2 was also implicated in the up-regulation of type I IFNs: a recent study 
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demonstrated that it interacts with single-stranded viral RNA leading to the activation of the 
adaptor molecule MAVS and to the subsequent induction of IFNβ (Sabbah, et al., 2009). 
NOD1 and NOD2 not only sense PAMPs of cytosolic, but also of extracellular pathogens, 
because extracellular ligands can be delivered into the cytosol via transporter systems. A 
recently described transporter system is the oligopeptide transporter hPepT1, which is able 
to transfer bacterial peptides, such as fMLP and MDP, into the cytosol (Charrier and Merlin, 
2006). After reaching the cytosol via hPepT1, MDP was shown to stimulate the activation of 
NF-κB via NOD2. This oligopeptide transporter is expressed in the intestinal epithelium, but 
also on human monocytes and could therefore have a central function in the activation of 
NOD2 by extracellular pathogens (Charrier, et al., 2006). Moreover, other pathways for 
PAMPs to gain access to the cytosol have been described. Pore-forming toxins from some 
bacterial strains could damage the plasma or endosomal membranes by forming large pores. 
These in turn could subsequently allow extracellular PAMPs to gain access to the cytosol, as 
has been suggested for group B streptococcus (Charrel-Dennis, et al., 2008) and for S. 
pneumoniae during nasopharyngeal colonization (Davis, et al., 2011). Furthermore, type IV 
secretion systems have been described to transport bacterial components that could 
potentially act as PAMPs (Lippmann, et al., 2011; Nagai and Roy, 2003). Thus, several 
transport mechanisms have been described that translocate PAMPs from the extracellular 
space into the cytosol. It is conceivable that further mechanisms exist to provide the manifold 
intracellular PRRs with pathogen-derived ligands. 
The other group of NLRs is known to form inflammasomes. Inflammasomes are composed of 
an NLR (for example NLRP3), pro-caspase-1, and the adaptor molecule ASC, although the 
latter can be dispensable for some inflammasomes (Schroder and Tschopp, 2010). Upon 
stimulation of the NLR, the inflammasome protein complex assembles and pro-caspase-1 is 
autoproteolytically cleaved into its active form. The active caspase-1 can subsequently 
cleave the inactive pro-forms of some cytokines, e.g. pro-IL-1β and pro-IL-18 into their 
biologically active forms (de Veerdonk, et al., 2011). The NLRP3 inflammasome can be 
activated by various stimuli not only after infection with pathogens, but also in response to 
endogenous danger signals (DAMPs) or xenocompounds such as asbestos or aluminum 
hydroxide. This suggests that NLRP3 itself is not a PRR but indicates the existence of 
several sensing pathways that culminate in the activation of the NLRP3 inflammasome 
(Leemans, et al., 2011).  
Moreover, inflammasomes mediate a caspase-1-dependent programmed cell death known 
as pyroptosis, which is involved in restricting the replication of some intracellular pathogens 
(Miao, et al., 2011). Thus, inflammasomes are important regulators of the pro-inflammatory 
response and have a central role in the host defense.  
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1.2.2.3 RIG-I-like receptors 
The group of RIG-I-like receptors (RLRs) is composed of three members whose function is 
the recognition of cytosolic RNA via their DExD/H box RNA helicase domain (Loo and Gale, 
2011). RIG-I (DDX58) senses short ssRNA and dsRNA with a 5’ phosphate end, whereas 
MDA5 detects longer dsRNA substrates. After sensing RNA, RIG-I and MDA5 recruit the 
adaptor molecule MAVS. MAVS then activates the transcription factors IRF3 and NF-κB and 
consequently leads to the induction of type I IFNs and pro-inflammatory cytokines (Loo and 
Gale, 2011). Another signaling cofactor of RIG-I can be the adaptor molecule STING, which 
is also involved in the signaling pathways activated by cytosolic DNA (Ishikawa and Barber, 
2008). 
Due to their ability to detect various types of cytosolic RNA, RLRs play an important role in 
the cellular defense against many viruses. The activation of the type I IFN response induces 
an anti-viral state in the infected and non-infected neighboring cells. Knockout mice deficient 
in RIG-I or MDA5 are more susceptible to infection with various RNA viruses (Kato, et al., 
2006). In addition, RLRs have a role in the detection of cytosolic DNA. It was demonstrated 
that cytosolic AT-rich DNA is converted to RNA by RNA polymerase III (Ablasser, et al., 
2009; Chiu, et al., 2009). This RNA is a ligand for RIG-I and induces the production of type I 
IFNs. The RNA polymerase III/RIG-I system thus functionally belongs to the cytosolic DNA 
sensing pathways (see also below). 
1.2.2.4 Cytosolic DNA sensors 
1.2.2.4.1 DAI 
The detection of cytosolic DNA is mediated by different systems. DAI (DNA-dependent 
activator of IFN regulatory factors; also known as ZBP-1) was the first cytosolic DNA sensor 
described that leads to the induction of IFNα/β (Takaoka, et al., 2007). However, 
macrophages or mouse embryonic fibroblasts from DAI-deficient mice did not show a defect 
in the induction of type I IFNs after DNA stimulation (Ishii, et al., 2008). Moreover, the siRNA-
mediated knockdown of DAI in an alveolar epithelial cell line did not influence the type I IFN 
response after infection with L. pneumophila (Lippmann, et al., 2008). This lack of a 
phenotype could be explained by the existence of several redundant DNA-sensing pathways 
in the cytosol, which lead to the transcription of type I IFNs.  
1.2.2.4.2 PYHIN proteins 
The PYHIN protein AIM2 belongs to the HIN200-domain family of proteins and has been 
recently described to sense cytosolic DNA (Burckstummer, et al., 2009; Fernandes-Alnemri, 
et al., 2010; Hornung, et al., 2009; Roberts, et al., 2009). AIM2 contains a HIN200-domain 
that mediates the DNA recognition and a pyrin domain that interacts with the inflammasome 
adaptor molecule ASC. Activation of AIM2 leads to the formation of an inflammasome and to 
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the subsequent production of mature IL-1β. AIM2 was shown to be involved in the host 
defense against DNA viruses (Rathinam, et al., 2010), the gram-negative bacterium 
Francisella tularensis (Fernandes-Alnemri, et al., 2010; Jones, et al., 2010), as well as the 
gram-positive bacterium L. monocytogenes (Kim, et al., 2010; Sauer, et al., 2010; Tsuchiya, 
et al., 2010; Warren, et al., 2010). Thus, AIM2 is playing an important role in the host 
defense against a broad range of pathogens. 
IFI16 is another member of the PYHIN protein family and is also able to sense DNA via its 
HIN200 domain. It was first described to mediate the induction of type I IFNs after 
transfection of DNA and after infection with DNA viruses, e.g. herpes virus (Unterholzner, et 
al., 2010). Moreover, it has been indicated that IFI16 might also have direct antiviral effects 
(Gariano, et al., 2012). Recent publications indicate additional functions of IFI16 in inhibiting 
the AIM2 inflammasome (Veeranki, et al., 2011) and in forming an inflammasome itself in 
and around the nucleus in response to Kaposi Sarcoma-associated herpesvirus infection 
(Kerur, et al., 2011). Thus, IFI16 is playing a multifaceted role in the host defense by 
stimulating both a type I IFN response as well as the production of inflammasome-dependent 
cytokines. For the induction of type I IFNs, IFI16 recruits the adaptor protein STING, which in 
turn relays the signal to activate the transcription factors IRF-3 and NF-κB. STING plays a 
central role in the defense against many different pathogens. Mice deficient in STING were 
more susceptible to infection with herpes simplex virus (Ishikawa, et al., 2009). Moreover, 
STING was essential for the type I IFN response after infection with L. monocytogenes 
(Ishikawa, et al., 2009; Sauer, et al., 2011) and L. pneumophila (Lippmann, et al., 2011). 
Apart from being involved in pathways that sense cytosolic DNA, STING has been recently 
shown to act as a PRR that detects and directly binds to cyclic di-GMP, which also results in 
the induction of type I IFNs (Burdette, et al., 2011). Cyclic di-GMP is a prevalent second 
messenger molecule in many bacteria that controls processes, such as flagellar motility, 
biofilm formation, and cell cycle regulation (Mills, et al., 2011). Thus, STING is a central 
protein in the initiation of the type I IFN response after detection of different PAMPs in the 
cytosol. 
1.2.2.4.3 RIG-I 
Even though the helicase RIG-I (DDX58) can only directly sense RNA molecules in the 
cytosol, it has also been implicated in the recognition of DNA (Ablasser, et al., 2009; Chiu, et 
al., 2009). Poly dA:dT DNA was shown to be converted into an RNA intermediate by the 
RNA polymerase III in the cytosol. This intermediate can be then sensed by RIG-I, which 
leads to the induction of type I IFNs via the pathway described above (see 1.2.2.3). 
In conclusion, cytosolic DNA is sensed by different receptor systems that mostly converge in 
the activation of the transcription factors IRF-3 and/or IRF-7 as well as NF-κB and 
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consequently lead to the activation of type I IFNs and pro-inflammatory cytokines. However, 
some are able to form inflammasomes after sensing DNA and contribute to the production of 
IL-1β and IL-18. 
1.2.3 Innate immune recognition of S. pneumoniae 
1.2.3.1 Toll-like receptors 
The innate immune response to S. pneumoniae has been investigated during the last years. 
The membrane-bound TLRs as well as cytosolic PRRs were shown to be involved in the host 
defense against pneumococci (see below). After infection with S. pneumoniae TLR2, -4, and 
-9 have been shown to play a role in the recognition of this pathogen (Albiger, et al., 2007; 
Knapp, et al., 2004; Malley, et al., 2003). An overview which TLR pathways contribute to 
sensing S. pneumoniae and what ligands they recognize is given in Fig. 1.  
TLR2 is the most thoroughly investigated TLR in pneumococcal infection. This receptor 
senses components of the cell wall of S. pneumoniae, such as peptidoglycan and lipoteichoic 
acid, in combination with the co-receptors CD14 and the lipopolysaccharide-binding protein 
(Schroder, et al., 2003; Schwandner, et al., 1999). Stimulation of TLR2 by S. pneumoniae in 
vitro led to the activation of NF-κB and to the production of cytokines and chemokines, such 
as TNFα, IL-6, IL-8, and KC (Knapp, et al., 2004; Mogensen, et al., 2006). In vivo, the role of 
TLR2 has been investigated in different models of pneumococcal infection. In a model of 
pneumococcal colonization, TLR2-/- mice had an increased bacterial burden of pneumococci 
during later stages of infection compared to wild-type mice (van Rossum, et al., 2005). 
Moreover, TLR2 has a pronounced role in S. pneumoniae-induced meningitis. TLR2-/- mice 
were more susceptible to disease than wild-type mice and had an increased disease 
progression and pneumococcal replication. Additionally, they succumbed earlier to the 
infection. Interestingly, the early influx of leukocytes into the cerebrospinal fluid also seemed 
to be dependent on TLR2 (Echchannaoui, et al., 2002; Koedel, et al., 2003). In a model of S. 
pneumoniae pneumonia, TLR2-/- mice displayed slightly reduced inflammation, cytokine 
levels and neutrophil influx (Knapp, et al., 2004). Surprisingly, a difference in mortality 
between the wild-type and knockout mice could only be observed after infection with PLY-
deficient pneumococci and not with the wild-type strain (Dessing, et al., 2008). 
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Fig. 1:  Recognition of S. pneumoniae by the innate immune system. Pneumococcal components, such as 
lipopeptides, PLY, or DNA are sensed by Toll-like receptors (TLRs) on the plasma membrane or in the 
endosomal compartment. Moreover, some pneumococcal cell wall components such as peptidoglycan 
can access the cytosol, where they are sensed by NOD2. All these receptors induce the activation of the 
transcription factor NF-κB and consequently lead to the production of cytokines and chemokines, such 
as TNFα, IL-6, KC, and pro-IL-1β. The latter is further processed into its mature and active form by 
inflammasomes that contain active caspase-1. The NLRP3 inflammasome is activated in response to 
pneumococcal PLY. In addition to stimulating NF-κB, NOD2 was also recently reported to contribute to 
type I IFN induction during pneumococcal colonization. To this date, it remains to be elucidated if other 
pneumococcal components are able to access the cytosol and activate innate immune pathways.  
The exact role of TLR4, the well-described receptor for LPS of gram-negative bacteria, 
during infection with S. pneumoniae remains controversial. In vivo studies demonstrated that 
TLR4-/- mice had a reduced survival and an enhanced bacterial replication during early time 
points of colonization and after pulmonary infection with small doses of S. pneumoniae 
(Branger, et al., 2004; Malley, et al., 2003). This could, however, not be observed in a model 
of pneumococcal sepsis (Benton, et al., 1997). Some studies implicated that pneumococcal 
PLY is a cognate ligand of TLR4, which is able to induce cytokine production (Malley, et al., 
2003; Srivastava, et al., 2005). However, others challenge this model by demonstrating a 
TLR4-independent cytokine production by PLY (McNeela, et al., 2010) and by demonstrating 
that TLR4 might also recognize DAMPs after acute lung injury (Imai, et al., 2008). The in vivo 
data clearly demonstrate a role of TLR4 during pneumococcal infection. However, the exact 
mechanism of TLR4 activation by S. pneumoniae requires further investigation. 
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TLR9 is the third toll-like receptor known to be involved in pneumococcal recognition. It is 
activated after sensing unmethylated CpG sequences in S. pneumoniae DNA. Hek-293 cells 
overexpressing TLR9 were responsive to both live pneumococci and pneumococcal DNA, 
resulting in the activation of NF-κB and the production of IL-8 (Mogensen, et al., 2006). Mice 
deficient in TLR9 had an impaired survival after intranasal, but not after intra-peritoneal 
challenge with S. pneumoniae. The bacteria were found to have an increased replication in 
the bronchi of TLR9-/- mice and also an increased dissemination into the lung tissue. The 
cytokine production in this model, however, was similar to the one in wild-type mice (Albiger, 
et al., 2007). 
As described above, the single TLR knockout mice did not show a severe phenotype after 
pneumococcal infection indicating a redundancy in TLR signaling on the activation of the 
innate immune response (Albiger, et al., 2007; Knapp, et al., 2004; Malley, et al., 2003). 
However, deficiency in MyD88, the central adaptor of TLR signaling and IL-1 receptor 
signaling, severely impaired the immune response to S. pneumoniae and greatly enhanced 
the susceptibility of the knockout mice to invasive disease (Albiger, et al., 2005; Khan, et al., 
2005; Koedel, et al., 2004). This indicates the existence of multiple yet partly redundant 
MyD88-depedent pathways that collectively activate the immune response. 
1.2.3.2 NOD-like receptors 
Bacterial components of S. pneumoniae are also sensed in the cytosol. After pneumococcal 
infection, NOD2 is stimulated, which triggers the activation of NF-κB (Opitz, et al., 2004) (see 
Figure 1). NF-κB subsequently induces the production of pro-inflammatory cytokines and 
chemokines. In vivo, NOD2 was involved in the initiation of the innate immune response via 
mediating the MCP-1-dependent recruitment of macrophages during pneumococcal 
colonization (Davis, et al., 2011). Moreover, this NLR also supports the activation of the 
adaptive immune response by contributing to the induction of antibody production. 
Additionally to a function during colonization of the nasopharynx, NOD2 was also shown to 
be important in a model of S. pneumoniae meningitis (Liu, et al., 2010). In contrast to their 
wild-type counterparts, mice deficient in NOD2 were found to have reduced levels of 
astrogliosis, demyelination, and inflammation. Accordingly, microglia and astroglia from 
NOD2-/- mice were found to secrete diminished amounts of TNFα, IL-6 and MIP-1α after in 
vitro infection with S. pneumoniae. 
Additionally to NOD2, another NLR was demonstrated to play a role in the innate immune 
response to S. pneumoniae. NLRP3 was activated by pneumococci, formed an 
inflammasome, and was thus contributing to the production of IL-1β by macrophages and 
DCs (Fang, et al., 2011; Hoegen, et al., 2011; McNeela, et al., 2010; Witzenrath, et al., 
2011). This activation was shown to be dependent on pneumococcal PLY. In vivo, NLRP3-/- 
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mice had a reduced pneumococcal clearance in the lung (McNeela, et al., 2010) as well as 
an impaired lung endothelial/epithelial barrier (Witzenrath, et al., 2011). In contrast, NLRP3 
knockout mice showed a reduced pathology and improved clinical scores in a model of 
pneumococcal meningitis (Hoegen, et al., 2011). This indicates a differential role of the 
NLRP3 inflammasome in different compartments of the organism during infection. 
Interestingly, significant levels of IL-1β were still detectable in NLRP3-/- cells and mice after 
pneumococcal infection (Fang, et al., 2011; McNeela, et al., 2010; Witzenrath, et al., 2011). 
Thus, other inflammasomes are likely to contribute to the IL-1β response during infection with 
S. pneumoniae. 
1.2.4 Innate immune effectors 
1.2.4.1 Type I interferons 
Type I interferons (IFNs) are a group of 14 IFNα genes, 1 IFNβ gene, and several other still 
poorly characterized members (e.g. IFNε or IFNκ) (Decker, et al., 2005). They are produced 
during infections with viral or bacterial pathogens (Monroe, et al., 2010). The various cellular 
pathways leading to the induction of type I IFNs are summarized in Figure 2. Stimulation of 
the membrane-bound TLRs or various cytosolic nucleic acid sensors induces the recruitment 
of adaptor molecules (MyD88, STING, TRIF, MAVS) and the subsequent activation of the 
transcription factors IRF-3 and/or IRF-7. These bind to the promoter regions of type I IFN 
genes and induce the transcription, production, and secretion of these cytokines. Moreover, 
the promoter region of the IFNβ gene contains additional binding sites for the transcription 
factors NF-κB (Thanos and Maniatis, 1992) and ATF2/c-jun (Du, et al., 1993). The 
coordinated binding of all transcription factors in the promoter region cooperatively stimulates 
a strong transcription of the IFNβ gene (Wathelet, et al., 1998). 
After secretion, type I IFNs bind to the IFNα/β receptor (IFNAR) and activate downstream 
signaling cascades that involve the Jak-Stat pathway (de Weerd, et al., 2007). This leads to 
the formation of the ISGF3 complex consisting of STAT1, STAT2 and IRF9, which acts as a 
transcription factor and binds to ISRE sites in the promoters of interferon-stimulated genes 
(ISGs). Moreover, IFNAR activation also induces the activation of GAF, a Stat-1 homodimer, 
that binds to the GAS elements in ISG promoter regions (Decker, et al., 2005). 
Type I IFNs have a broad range of biological effects that modulate the immune response to 
various pathogens. In some infections this can be beneficial, whereas in others the overall 
effect of IFNα/β is detrimental to the host. The first described effect of type I IFNs was its 
ability to confer an “anti-viral state” to infected and non-infected neighboring cells (Isaacs and 
Lindenmann, 1957). This is achieved by inducing anti-viral ISGs, such as Mx proteins, IFITM 
proteins, and Viperin, which inhibit the intracellular viral replication (Liu, et al., 2011).  
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Fig. 2: Cellular signaling pathways that lead to the induction of type I IFNs. TLRs on the plasma 
membrane or in the endosome recognize microbial components or nucleic acids and signal via the 
adaptor proteins MyD88 or TRIF to activate IRF-3/-7 transcription factors. NOD2 and RLRs can sense RNA 
components and activate type I IFNs via IRF-3/-7. RLRs signal via the adaptor proteins MAVS. DNA is 
sensed by a diverse group of cytosolic receptors. Most signal via the adaptor protein STING, although 
also STING-independent pathways (e.g. DNA polymerase III/RIG-I pathway) have been described. 
Moreover, STING is also able to directly sense cyclic di-GMP (c-di-GMP). All DNA sensors finally activate 
the transcription factors IRF-3 and/or IRF-7, which in turn stimulate the transcription of type I IFNs 
Moreover, type I IFNs also induce ISGs with anti-bacterial functions. A prominent example 
for this is the inducible nitric oxide synthase (iNOS), which has been shown to be positively 
regulated by IFNα/β, which has protective effects against pathogens such as Chlamydia 
trachomatis (Devitt, et al., 1996) and Burkholderia pseudomallei (Utaisincharoen, et al., 
2003). Moreover, type I IFNs (often together with type II IFN) induce the enzyme indoleamine 
2,3-dioxygenase that restricts the availability of tryptophan (Puccetti, 2007) and thus inhibits 
the growth of pathogens including Streptococci, Enterococci, and Chlamydophila 
pneumoniae (Daubener and MacKenzie, 1999; Njau, et al., 2009). Additionally, a group of 
p47 GTPases, also known as the IRG proteins, were shown to be important for the defense 
against intracellular pathogens, e.g. L. pneumophila and Toxoplasma gondii (Howard, 2008). 
Early studies reported that type I IFNs are able to inhibit the invasion of Salmonella and 
Shigella bacteria into epithelial cells (Bukholm, et al., 1984; Niesel, et al., 1986). This 
indicates yet another protective effect of IFNα/β against some bacteria. However, the exact 
mechanism of this inhibition remains to be elucidated. 
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Additionally to inducing a number of anti-viral and anti-bacterial ISGs, type I IFNs sensitize 
cells to undergo apoptosis. This effect has been described for macrophages and 
lymphocytes during infection with Listeria monocytogenes (Carrero, et al., 2004; Stockinger, 
et al., 2002). While in viral infection, type I IFN-mediated apoptosis of infected host cells 
could limit the proliferation of the virus, during infection with Listeria, this mechanism 
promotes the death of important immune cells and is detrimental to the host (Carrero and 
Unanue, 2012).  
Type I IFNs also influence the expression of several cytokines. They were shown to stimulate 
the production of type II IFN, also known as IFNγ, together with IL-18 during infection with 
Salmonella typhimurium (Freudenberg, et al., 2002). Moreover, a contribution of type I IFNs 
to IFNγ production was also observed in mice infected with L. monocytogenes (Carrero, et 
al., 2006). Additionally to influencing the secretion of type II IFN, IFNα/β also down-regulates 
the surface expression of the IFNγ receptor (IFNGR) on immune cells, including 
macrophages and dendritic cells (Rayamajhi, et al., 2010). This renders the cells less 
responsive to activation by IFNγ and consequently modulates the immune response. 
Additionally to type II IFN, the cytokine IL-1β is also regulated by type I IFNs on different 
levels. Stimulation of cells with IFNα/β led to reduced mRNA-levels of the precursor pro-IL-1β 
(Guarda, et al., 2011; Novikov, et al., 2011), which was proposed to occur via the induction of 
the anti-inflammatory cytokine IL-10. Moreover, type I IFNs appeared to diminish the post-
translational processing of pro-IL-1β by inhibiting the NLRP1 and NLRP3 inflammasomes 
(Guarda, et al., 2011). However, IFNα/β does not only have inhibiting effects on 
inflammasomes since it was shown to induce the AIM2 inflammasome, which was required 
for defense against Francisella infection (Choubey, et al., 2010; Fernandes-Alnemri, et al., 
2010). Thus, depending on the type of infection type I IFNs can have both inhibiting and 
stimulating effects on IL-1β. 
Apart from regulating the production of cytokines, the influence of IFNα/β on the expression 
of several chemokines has also been demonstrated. It was shown that the chemokine MCP-
1 was induced and required for the recruitment of macrophages during infection with L. 
monocytogenes and S. pneumoniae (Antonelli, et al., 2010; Davis, et al., 2011; Jia, et al., 
2009). However, in the model of S. pneumoniae infection, the expression of this chemokine 
was inhibited by high levels of type I IFNs elicited by a preceding influenza infection 
(Nakamura, et al., 2011). Moreover, an inhibiting effect of IFNα/β could be observed for the 
neutrophil-recruiting chemokines KC and MIP-2 in a similar model (Shahangian, et al., 2009). 
Type I IFNs also influence the T cell response during infection. It was described that they 
negatively regulate the production of the cytokine IL-17 produced by the subset of γδ-T cells 
(Henry, et al., 2010). This was linked to a reduced recruitment of neutrophils in an infection 
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with Francisella. In accordance, type I IFNs were shown to induce IL-27, a negative regulator 
of IL-17 production (Guo, et al., 2008). 
In vivo, Type I IFNs are required in the defense against many viruses (Bogdan, 2000; Zhang, 
et al., 2008). Moreover, their role in the defense against some bacteria has been begun to be 
characterized during the last years. Type I IFNs had protective effects for the host in a 
murine model of L. pneumophila pneumonia (Lippmann, et al., 2011). Moreover, they were 
required in the defense against systemic infection with group B streptococcus and E. coli 
(Mancuso, et al., 2007). However, in other bacterial infections, such as L. monocytogenes or 
Mycobacterium tuberculosis, the induction of type I IFNs contributed to a worse outcome for 
the host (O'Connell, et al., 2004; Stanley, et al., 2007). IFNAR-/- mice infected with Listeria 
had reduced bacterial loads in the liver and the spleen as well as a strongly enhanced 
survival compared to wild-type mice (O'Connell, et al., 2004). Similarly, after infection with M. 
tuberculosis, these knockout mice had fewer bacteria in the spleen than their wild-type 
counterparts (Stanley, et al., 2007). Thus the overall effect of type I IFNs on the host defense 
in vivo varies in different infection models. 
1.2.4.2 Type II interferon 
Type II interferon, also known as IFNγ, mediates different effects in the innate and the 
adaptive immune response. Producers of IFNγ include natural killer T cells and other T 
lymphocytes, neutrophils, macrophages, and dendritic cells (Schroder, et al., 2004; Yamada, 
et al., 2011). Whereas the local production of IFNγ by natural killer T cells, macrophages, 
and dendritic cells may be important in the early activation of infected and non-infected 
neighboring cells, T lymphocytes are the main producers of type II IFN during the following 
adaptive immune response (Brigl, et al., 2011; Schroder, et al., 2004). The induction of type 
II IFN occurs via the interleukin IL-12, which is secreted by e.g. DCs after infection. IL-12 
induces IFNγ production in the recruited neutrophils, natural killer T cells, and other T 
lymphocytes. IL-18 is secreted by APCs after inflammasome activation and further enhances 
the production of IFNγ (Schroder, et al., 2004). 
After secretion, IFNγ binds to the IFNγ receptor (IFNGR), which is composed of two 
homodimers (IFNGR1 dimer and IFNGR2 dimer). This binding activates a downstream 
signaling cascade leading to the JAK-dependent phosphorylation of transcription factors, e.g. 
Stat-1. However, the activation of JAK-Stat independent pathways after stimulation with IFNγ 
has also been described (Gough, et al., 2008). Stat-1 homodimerizes to form the GAF 
transcription factor, then translocates into the nucleus, and finally stimulates the transcription 
of a variety of interferon-stimulated genes that contain GAS elements in their promoter 
regions. Moreover, type II IFN can also induce the ISGF3 complex (see above), which leads 
to the transcription of genes with ISRE elements in their promoters (Morrow, et al., 2011). 
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Thus, there is a substantial overlap in ISGs induced by type I and type II IFNs. However, 
both types of IFN also stimulate the expression of some other ISGs exclusively (Schroder, et 
al., 2004). 
Type II IFN has a broad variety of functions in activating the innate immune system and 
shaping the adaptive immune response. It induces chemokines and adhesion molecules that 
attract immune cells to the site of infection (Gil, et al., 2001; Rollins, et al., 1990; Schroder, et 
al., 2004). Recruited neutrophils and macrophages are activated by IFNγ to produce reactive 
oxygen species (ROS) and reactive nitrogen intermediates, which mediate the killing of both 
intracellular and extracellular pathogens. Moreover, type II IFN (as well as type I IFNs) can 
prime the recruited neutrophils to promote the formation of Neutrophil Extracellular Traps 
(NETs) that have a broad anti-microbial function (Martinelli, et al., 2004; Papayannopoulos 
and Zychlinsky, 2009). Additionally, IFNγ leads to the enhancement of phagocytosis 
neutrophils and antigen presentation on MHCI and MHCII complexes. IFNγ also leads to the 
induction of antiviral ISGs, such as PKR. In terms of shaping the adaptive immune response, 
type II IFN promotes the development of a Th1 response (Schroder, et al., 2004). 
Mice deficient in IFNγ signaling show an enhanced susceptibility to viral, bacterial, and 
parasitic infections (Shtrichman and Samuel, 2001). Type II IFNs contribute to anti-viral 
immunity, e.g. against hepatitis B virus (Guidotti, et al., 2000) and herpes simplex virus 
(Cantin, et al., 1999). However, their role in the anti-microbial defense against intracellular 
pathogens is much more prominent. Mice deficient in IFNγ signaling were more susceptible 
to infection with various pathogens including L. monocytogenes (Huang, et al., 1993), S. 
typhimurium (Mastroeni, et al., 1999), and M. tuberculosis (Flynn, et al., 1993). Moreover, 
type II IFN was shown to be important for the immune response to parasitic infections with 
Leishmania major (Wang, et al., 1994). Thus, IFNγ plays an important part in mediating the 
immune response against a wide range of pathogens. 
1.3 Immune response to bacterial pneumonia  
The immune system has developed a vast array of mechanisms to sense and eliminate 
invading pathogens. Many pathogens that cause bacterial pneumonia, such as S. 
pneumoniae and Haemophilus influenza, can colonize the nasopharynx. One way of the host 
to counteract this colonization is the production of mucus. The mucus acts as a mechanical 
barrier, but also contains anti-microbial peptides and proteins (defensins, lysozyme, 
lactoferrin) as well as ROS (Ryu, et al., 2010). Moreover, the cilia on the epithelium induce a 
constant flow of the mucus towards the mouth and out of the airways. Additionally, the 
colonization of the nasopharynx induces immediate innate immune responses via PRRs 
including TLRs and NLRs, which leads to the expression of chemokines, such as KC, MCP-
1, or RANTES (Bootsma, et al., 2007; Davis, et al., 2011; Palaniappan, et al., 2006). These 
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chemokines recruit and/or activate cells of the innate (neutrophils, monocytes/macrophages) 
and adaptive (T cells, B cells) immune system that mediate the clearance of the bacteria. 
Defects in the recruitment process of immune cells, but also the impairment of the epithelial 
barrier integrity during extravasation of phagocytes present opportunities for the bacteria in 
the nasopharynx to invade into the surrounding tissue and to access the sterile lower 
respiratory tract (LRT) (Clarke, et al., 2011; Palaniappan, et al., 2006). In the LRT, bacteria 
encounter several antimicrobial mechanisms that assist in clearance of the pathogens. Type 
II alveolar epithelial cells produce surfactant proteins that have anti-bacterial functions. 
Surfactant protein D can interact with and aggregate microbes, which makes them more 
accessible to neutrophil phagocytosis or mucocilliary clearance (Hartshorn, et al., 1998). 
Moreover, microbe-bound surfactant proteins A and D are able to activate alveolar 
macrophages (Gardai, et al., 2003). Additionally to the binding of surfactant proteins, 
components of the complement system opsonize invading pathogens. These can involve the 
binding of the complement protein C1q to secretory IgM antibodies bound to bacteria 
(classical pathway) or of the mannan binding lectin to carbohydrate moieties on the surface 
of microbes (lectin pathway). Activation of the complement pathway enhances the 
phagocytosis of the opsonized bacteria and/or leads to their direct lysis. Some complement 
factors have chemotactic properties and recruit phagocytic cells (Skattum, et al., 2011). 
Apart from being opsonized by surfactant proteins and complement factors, bacteria are 
directly sensed by alveolar macrophages and dendritic cells via PRRs. This leads to the 
activation of NF-κB and IRF transcription factors in these cells and to the production of pro-
inflammatory cytokines including IL-1β, TNFα, and IL-12 (Mizgerd, 2008). Invariant Natural 
killer T cells (iNKT cells) contribute to the innate immune activation by sensing bacterial 
glycolipids presented on APCs (Boyton, 2008; Kinjo, et al., 2011). This leads to the 
production of IFNγ and IL-17A. After secretion, the cytokines IL-1β, TNFα, and IL-17A 
activate the NF-κB pathway in neighboring alveolar epithelial cells. This NF-κB activation (in 
both immune and epithelial cells) leads to the production of chemokines (KC, MIP-2, CXCL5) 
attracting neutrophils to the site of infection. Moreover, TNFα regulates e.g. the expression of 
neutrophil-adhesion molecules on the endothelium (Craig, et al., 2009).  
Stimulation of PRRs induces also the production of other cytokines, such as type I IFNs. 
These induce many anti-viral and anti-bacterial ISGs and mediate immunity against some 
intracellular bacteria (Lippmann, et al., 2011). Moreover, GM-CSF is also produced in a 
TLR4-dependent manner (Standiford, et al., 2011). GM-CSF is a growth factor that 
stimulates proliferation and differentiation of various cell types including macrophages and 
alveolar epithelial cells. It was shown to have protective effects in bacterial pneumonia of 
gram-negative (Standiford, et al., 2011) and gram-positive bacteria (Steinwede, et al., 2011). 
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Neutrophils are the main phagocytic cells that eliminate the bacteria in the airways. After 
recruitment by the above mentioned mechanisms, they generate pro-inflammatory signals, 
such as IFNγ (Yamada, et al., 2011), IL-18 (Sporri, et al., 2008), and chemokines 
(Borregaard, et al., 2007). These chemokines induce further recruitment of immune cells. IL-
18 activates different cell types including neutrophils and NK cells and further promotes the 
production of type II IFN (Fortin, et al., 2009; Sporri, et al., 2008). The IFNγ activates 
neutrophils to enhance phagocytosis and to produce ROS (Yamada, et al., 2011). Apart from 
eliminating bacteria by phagocytosis, neutrophils contain granules with antimicrobial peptides 
and enzymes (e.g. neutrophil elastase, GpIIA-PLA2) that are released during infection 
(Borregaard, et al., 2007; Moraes, et al., 2006). Moreover, they can constrain and kill 
bacteria by producing neutrophil extracellular traps (NETs). NETs are composed of 
decondensed chromatin and antimicrobial proteins. They restrict bacterial spreading and 
provide a scaffold to enhance the local concentration of antimicrobial proteins 
(Papayannopoulos and Zychlinsky, 2009). However, some bacteria, such as S. pneumoniae, 
can counteract entrapment by NETs by expressing endonucleases (Beiter, et al., 2006). 
Additionally to shaping the innate immune response, DCs migrate to the peripheral lymph 
nodes and activate T cells, which in turn can stimulate B cells. This leads to the production of 
antibodies by B cells and to anti-microbial T cell responses. In general, T cells are divided 
into several subsets including T helper cells, cytotoxic T cells, and natural killer T cells. 
Together they shape the immune response in the lung. Both CD8+ T cells and Th1/Th17 cells 
have been shown to contribute to the host defense in bacterial pneumonia (Bai, et al., 2009; 
Olliver, et al., 2011; Weber, et al., 2011). Th17 cells, however, are most important for fighting 
pneumonia caused by extracellular bacteria. 
In order to avoid excessive lung injury elicited by the antimicrobial mechanisms during the 
immune response, anti-inflammatory factors and pathways are activated. Negative feedback 
mechanisms are important since the damage produced by the defense mechanisms can be 
as lethal as the infection itself. These mechanisms include the production of anti-
inflammatory cytokines, such as IL-10, and of lipid molecules including lipoxins, resolvins, 
and protectins (Carlo and Levy, 2010; Mizgerd, 2008; Seki, et al., 2010).  
In order to achieve an optimal immune response to bacterial infection in the lung, a fine 
balance between the innate immune system, the adaptive immune system, and tissue-
preserving anti-inflammatory pathways is required. 
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1.4 Aim of this study 
Type I IFNs are important regulators of the immune system. They induce the expression of 
hundreds of bona-fide ISGs, and have been shown to regulate (positively or negatively) the 
production of mediators of the innate and the adaptive immune response. The role of type I 
IFNs in bacterial infections, however, has only begun to be characterized during the last 
years. While IFNα/β was shown to have detrimental effects in infections with L. 
monocytogenes and M. tuberculosis (O'Connell, et al., 2004; Stanley, et al., 2007), they had 
a protective role in infections with L. pneumophila and group B streptococcus (Lippmann, et 
al., 2011; Mancuso, et al., 2007). However, in S. pneumoniae infection, neither the pathway 
of type I IFN induction, nor their role in primary pneumococcal pneumonia have been 
investigated. 
The aims of this study were: (I) to investigate the bacterial requirements necessary for a type 
I IFN response; (II) to characterize the cellular pathways leading to the induction of type I 
IFNs after pneumococcal infection; (III) to analyze the impact of autocrine and paracrine type 
I IFNs on macrophages and neighboring epithelial cells; and (IV) to investigate the function of 
type I IFNs in pneumococcal pneumonia in mice. 
This study will contribute to the characterization of a novel pathway activated by S. 
pneumoniae, which is a part of the innate immune response. The investigation of its effects 
on cytokines and chemokines and of its role during pneumococcal pneumonia in vivo will 
contribute to a detailed understanding of the innate immune response. This will hopefully 
foster the development of new therapeutic strategies in order to fight pulmonary infections of 
S. pneumoniae in the future.  
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2. Results 
2.1 Streptococcus pneumoniae infection leads to the induction of type I 
interferons dependent on the virulence factor pneumolysin 
First, I investigated if S. pneumoniae induces type I IFNs in macrophages and what bacterial 
factors are involved in this induction. The infection of murine bone marrow-derived 
macrophages (BMMs) with a S. pneumoniae serotype 2 strain (D39) led to an induction of 
IFNβ on both mRNA and protein levels (Fig. 3A, B). A strain deficient for the capsule (D39 
Δcps) was also fully capable of inducing type I IFNs and even showed slightly enhanced 
IFNβ mRNA levels. However, the IFNβ induction was dependent on the pore-forming toxin 
pneumolysin (PLY), since PLY-deficient strains (D39 Δply, D39 ΔcpsΔply) did not cause an 
induction of IFNβ. The induction of type I IFNs after pneumococcal infection was also 
detected in human alveolar macrophages (Fig. 3C) and peripheral blood mononuclear cells 
(PBMCs; data not shown), but not in the human alveolar epithelial cell line A549 (Fig. 3D) or 
in primary murine lung alveolar epithelial cells (see Fig. 11C).  
This type I IFN induction was neither strain- nor serotype-specific, since infection with a 
serotype 4 strain derived from a clinical isolate (TIGR4) also led to a significant increase of 
IFNβ production in BMMs (Fig. 3E). However, the magnitude of induction was much less 
compared to the D39 wild-type strain. In contrast, the capsule-deficient TIGR4 strain (TIGR4 
Δcps) induced comparable IFNβ levels to D39. This induction was also dependent on PLY 
since the TIGR4 ΔcpsΔply strain showed an abrogated induction of type I IFNs (Fig. 3F).  
Considering that S. pneumoniae stimulated the production of type I IFNs in different 
phagocytes but not in lung epithelial cells, which are not actively phagocytosing, I 
hypothesized that the different magnitudes of IFNβ induction by D39 and TIGR4 strains 
might depend on an unequal phagocytic uptake of the pneumococci. Indeed, the amount of 
type I IFN mRNA levels correlated with the amount of phagocytosed S. pneumoniae. TIGR4 
wild-type pneumococci were only weakly phagocytosed by BMMs as opposed to D39 wild-
type (Fig. 3G). Capsule-deficient strains were always more strongly ingested than their wild-
type counterparts, which also correlated with an enhanced type I IFN induction (Fig. 3A, F).  
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Fig. 3: Type I IFNs are induced in macrophages after infection with S. pneumoniae in macrophages 
dependent on PLY. (A) C57BL/6 wild-type BMMs were infected with D39 wild-type, Δply, Δcps, or 
ΔcpsΔply pneumococci for 6h with a MOI 0.025 or 2.5. (B) Wild-type BMMs were infected with D39 wild-
type (MOI 0.025) for 18 h. (C) Human alveolar macrophages were infected with D39 wild-type or Δply (MOI 
2.5) for 6h. (D) Human broncho-alveolar epithelial cells (A549) were either infected with D39 wild-type (MOI 
0.025 or 2.5) or transfected with 0.25 µg poly dA:dT using Lipofectamine 2000 for 6 h. (E) Wild-type BMMs 
were infected with TIGR4 wild-type pneumococci (MOI 0.025 or 2.5) for 6h. (F) Wild-type BMMs were 
infected with TIGR4 Δcps or TIGR4ΔcpsΔply (MOI 0.025 or 2.5) for 6h. (G) BMMs from C57BL/6 mice were 
infected with either D39 or TIGR4 (wild-type or Δcps, MOI 2.5) for 1h. Internalized bacteria were 
determined as described. mIFNβ mRNA levels were determined by quantitative RT-PCR. IFNβ in the 
supernatant was quantified by ELISA. Experiments were performed twice (B, G) or at least three times (A, 
C-F) in duplicates (A-D) or triplicates (E-G). Figures show the mean + SEM of either a representative 
experiment (A, B, D) or the combined data (C, E-G). Where possible, statistical analysis was performed as 
described. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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Because the expression of PLY was essential for the type I IFN induction by both D39 and 
TIGR4 pneumococci, I tested if PLY alone would be sufficient to trigger the IFNβ induction. 
The incubation of human PBMCs with purified recombinant PLY did not lead to the induction 
of type I IFNs in contrast to poly I:C, which was used as a positive control (Fig. 4A). The 
purified PLY was biologically active, since it was fully capable of eliciting the release of IL-1β 
from the cells (Fig. 4B) as previously described (Witzenrath, et al., 2011). Thus PLY is 
necessary, but not sufficient for the type I IFN induction in response to S. pneumoniae 
infection. 
 
Fig. 4: Purified recombinant PLY is not sufficient to induce type I IFNs in macrophages. Human PBMCs 
were stimulated with PLY (2 µg/ml) or poly I:C (pIC, 0.5 µg/ml) for 16 h. hIFNβ mRNA levels were 
determined by quantitative RT-PCR. IL-1β in the supernatant was quantified by ELISA. Data shown are 
mean + SEM of a representative of three independent experiments carried out in duplicates.  
2.2 The type I IFN response to Streptococcus pneumoniae is dependent on 
bacterial uptake and endosomal acidification 
To further characterize the requirements for a type I IFN induction, BMMs were incubated 
with inhibitors for actin polymerization (Fig. 5A, C) or endosomal acidification (Fig. 5B, D). 
Inhibition of action polymerization with cytochalasin D renders the cell unable to phagocytose 
and abrogated the type I IFN induction after infection with D39 wild-type (Fig. 5A) or TIGR4 
Δcps pneumococci (Fig. 5C). These results are in agreement with the data shown above 
indicating that the type I IFN response occurs only in cells capable of phagocytosis (Fig. 3A, 
D, G). Additionally to the phagocytic uptake of S. pneumoniae, the acidification of the 
endosomal compartment is also important in the induction of type I IFNs. Pre-incubation of 
BMMs with the endosomal acidification inhibitors bafilomycin A1, chloroquine, or ammonium 
chloride, reduced the IFNβ induction after pneumococcal infection with D39 wild-type (Fig 
5B) or TIGR4 Δcps (Fig 5D) strains. Thus, the phagocytic uptake as well as the endosomal 
acidification are important steps in the initiation of the type I IFN responses to S. pneumoniae 
infection. 
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Fig. 5: The type I IFN response is dependent on the phagocytic uptake of the bacteria as well as on the 
acidification of the endosome. (A, C) C57BL/6 wild-type BMMs were pre-treated with 2 µM Cytochalasin D 
for 30 min before infection with (A) D39 wild-type (MOI 0.025 or 2.5, 6 h) or (C) TIGR4 Δcps (MOI 2.5, 6 h). 
(B, D) Wild-type BMMs were stimulated with 200 nM bafilomycin A1, 50 µM chloroquine, or 5 mM 
ammonium chloride for 30 min and then infected with (C) D39 wild-type (MOI 2.5, 6 h) or (D) TIGR4 Δcps 
(MOI 2.5, 6 h). mIFNβ mRNA levels were determined by quantitative RT-PCR. Data shown are 
representatives of two (C, D) or three (A) independent experiments or as mean ±SEM of three independent 
experiments (B) carried out in duplicates (A, B) or triplicates (C, D). Where possible, statistical analysis 
was performed as described. *** = p < 0.001. 
2.3 Type I IFN responses to pneumococcal infection appear to be 
dependent on intracellular recognition of bacterial DNA 
Since PLY was required, but not sufficient for the induction of type I IFNs, other 
pneumococcal PAMPs must exist that contribute to the activation of downstream signaling 
pathways. Because the uptake of the bacteria into the cell was required for the IFNα/β 
response (see Fig 3 and 5), I produced S. pneumoniae extracts and transfected them into 
BMMs. 
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This transfection caused the induction of IFNβ in these cells (Fig. 6A), which indicates that 
some pneumococcal components are generally capable of inducing type I IFNs upon delivery 
into the cytosol. Moreover, extracts from both D39 wild-type and D39 Δply strains elicited 
similar amounts of IFNβ induction after transfection into macrophages (Fig. 6A). Interestingly, 
digestion of D39 wild-type extracts with DNase, RNaseA, RNaseH, or proteinase K before 
transfection demonstrates that only the digestion with DNase led to an abrogation of the 
IFNβ induction (Fig. 6B). Moreover, the transfection of purified S. pneumoniae DNA into 
BMMs also elicited an increase in IFNβ mRNA levels (Fig. 6C).  
 
Fig. 6: The induction of type I IFNs appears to be dependent on the intracellular recognition of DNA. (A, B) 
Extracts from (A) D39 wild-type and Δply strains or from (B) D39 wild-type strain digested with DNase, 
RNases, or proteinase were transfected into C57BL/6 wild-type BMMs for 6 h. (C) S. pneumoniae DNA 
(0.25 µg per well) was transfected into wild-type BMMs. (D, E) Wild-type BMMs were transfected with 
siRNAs against AIM2 or with an unspecific control siRNA (siC) for 48 h before infection with D39 wild-type 
(MOI 0.025) for 16 h. mIFNβ (A-C) or mAIM2 (D) mRNA levels were determined by quantitative RT-PCR. 
mIL-1β in the supernatant was measured by ELISA. Data shown are representatives of two (A, D) or three 
(B, C, E) experiments carried out in duplicates (A-D) or triplicates (E). 
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These results indicate that pneumococcal DNA is generally capable of inducing type I IFNs in 
BMMs. However, the delivery of DNA into the cytosol via transfection is artificial and might 
not reflect the physiological situation during an infection. Thus, to prove that DNA is indeed 
present in the host cell cytosol during S. pneumoniae infection, I examined if AIM2, a well-
characterized cytosolic DNA sensor is activated by pneumococci. AIM2 belongs to the family 
of PYHIN proteins and forms an inflammasome after sensing e.g. microbial DNA in the 
cytosol of host cells (see above). This inflammasome processes pro-IL-1β into its mature 
form. Thus, the examination if the IL-1β production during pneumococcal infection is 
dependent on AIM2 indicates whether DNA is generally present in the cytosol during 
infection with S. pneumoniae. Indeed, the knockdown of AIM2 by two different siRNAs (Fig. 
6D) led to a strong decrease in the IL-1β production after pneumococcal infection (Fig. 6E). 
This indicates that the AIM2 inflammasome is involved in sensing S. pneumoniae and that 
DNA – probably of pneumococcal origin – is present in the cytosol during infection. Taken 
together, recognition of cytosolic DNA might be the PAMP that together with PLY is required 
for the induction of type I IFNs in S. pneumoniae-infected macrophages. 
2.4 Type I IFN induction by Streptococcus pneumoniae is dependent on 
STING, MyD88, and IRF3 
In order to identify the cellular signaling pathway that is involved in the induction of the type I 
IFN response, BMMs from several knockout mice (C57BL/6 background) were infected and 
the IFNβ mRNA levels in these cells were compared to the ones in wild-type cells. BMMs 
deficient in TLR2/3/4/7/9 or in the TLR3/4 adaptor TRIF did not show an impaired IFNβ 
induction compared to their wild-type counterparts (Fig. 7A, D). However, agonists for the 
respective TLRs failed to induce a response in the knockout cells (Fig. 7B, C, E, and data not 
shown). Surprisingly, BMMs deficient in the TLR adaptor MyD88 had a significantly reduced 
type I IFN response after infection with S. pneumoniae compared to the wild-type cells (Fig. 
7F). The knockout was functionally confirmed by showing the absent response of the 
MyD88-/- BMMs to the TLR2/4 agonists MALP2 and LPS (Fig. 7G). Thus, MyD88 – but not 
TLR2/3/4/7/9 or TRIF – is involved in the type I IFN response after pneumococcal infection. 
Next, I tested the involvement of several intracellular pathways that have been shown to be 
able to contribute to the induction of type I IFNs. BMMs from NOD2-/- mice showed an 
unaltered IFNβ induction compared to their wild-type counterparts after infection with S. 
pneumoniae (Fig. 8A). The functionality of the knockout was confirmed by detecting an 
almost absent IL-1β induction in these cells after stimulation with the NOD2 agonist MDP 
(Fig. 8B). Moreover, MAVS-/- BMMs showed a strong S. pneumoniae-induced IFNβ 
production (Fig. 8C), indicating that both the RNA-sensing RLRs and the DNA-sensing RNA 
PolIII/RIG-I pathway were not involved in this response. However, the knockout BMMs failed 
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to respond to the RIG-I agonists polyI:C and pppRNA (Fig. 8D), which confirmed that these 
cells were deficient in RIG-I signaling. Additionally, the involvement of IRF3, a central 
transcription factor for the initiation of the type I IFN response, was investigated. BMMs from 
IRF3-/- mice had a significantly abrogated IFNβ induction after infection with both D39 wild-
type (Fig. 8E) and TIGR4 Δcps (Fig. 8F) pneumococci. Thus, IRF3 – but not NOD2 or 
MAVS-related pathways – are required in the induction of type I IFNs in response to S. 
pneumoniae infection. 
 
Fig. 7: The type I IFN response after pneumococcal infection is dependent on MyD88. BMMs from C57BL/6 
wild-type or the respective knockout mice were infected with D39 wild-type strain (MOI 2.5, 6 h) (A, D, F), 
or stimulated with the respective PRR agonists for 6 h (B, C, E, G). mRNA levels of mIFNβ and mIL-1β 
were determined by quantitative RT-PCR. Infection experiments were performed three times in duplicates 
(A) or triplicates (D, F). Figures show the mean + SEM of either a representative experiment (B, C, E, G) or 
the combined data (A, D, F). Where possible, statistical analysis was performed as described. *** = p < 
0.001. 
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Fig. 8: The type I IFN response after pneumococcal infection is dependent on IRF3. BMMs from C57BL/6 
wild-type or the respective knockout mice were infected with D39 wild-type strain (A, C, E), TIGR4 Δcps 
strain (F) (MOI 2.5, 6 h), or stimulated with the respective PRR agonists for 6 h (B, D). mRNA levels of 
mIFNβ and mIL-1β were determined by quantitative RT-PCR. Data shown are representatives of at least 
three experiments carried out in duplicates. Infection experiments were performed three times in 
duplicates (A, C, E) or triplicates (F). Figures show the mean + SEM of either a representative experiment 
(A - E) or the combined data (F). Where possible, statistical analysis was performed as described. *** = p < 
0.001. 
In order to further elucidate cellular proteins involved in the type I IFN response to S. 
pneumoniae, RNA interference (RNAi) experiments were performed. The siRNA-mediated 
knockdown of STING (Fig. 9A), an adaptor protein for many cytosolic DNA sensors, led to a 
reduced IFNβ induction after infection with both D39 wild-type (Fig. 9B) and TIGR4 Δcps 
(Fig. 9C) pneumococci. Since this and earlier results indicate that pneumococcal DNA might 
be involved in the type I IFN response, I tested the involvement of two PRRs that have been 
described to detect DNA in the cytosol, DAI and IFI16. Knockdown of either protein with 
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different specific siRNAs (Fig. 9D, F) did not result in a strong reduction of the type I IFN 
response after pneumococcal infection (Fig. 9E, G). In the case of DAI, a tendency of 
reduction was detected. However, this effect seems negligible due to its small magnitude. 
Thus, STING is involved in the IFNα/β response to S. pneumoniae, but the cytosolic DNA-
sensing PRRs IFI16 and DAI do not play a non-redundant role in this signaling pathway. 
In summary, the adaptor molecules MyD88 and STING as well as the transcription factor 
IRF3 are involved in the type I IFN response after pneumococcal infection. 
 
Fig. 9: The type I IFN response after pneumococcal infection is dependent on STING. Wild-type BMMs 
were transfected with siRNAs specific for STING (A-C), DAI (D, E), IFI16 (F, G) or with unspecific control 
siRNA (siC) for 48 h prior to infection with D39 wild-type strain (B, E, G) or TIGR4 Δcps strain (C) (MOI 2.5, 
6 h). mRNA levels of mIFNβ were determined by quantitative RT-PCR. Experiments were performed at 
least three times in duplicates. Figures show the mean + SEM of representative experiments. 
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2.5 Type I IFNs regulate the production of RANTES in macrophages in an 
autocrine manner 
After investigating the pathways that lead to the type I IFN induction after pneumococcal 
infection, I then focused on the autocrine effects of type I IFNs on S. pneumoniae-infected 
macrophages. I investigated RANTES, a chemokine that was shown to be important in the 
host defense against S. pneumoniae (Palaniappan, et al., 2006). Indeed, type I IFNs induced 
by pneumococci stimulate the expression of the chemokine RANTES in BMMs on both 
mRNA and protein levels (Fig. 10A, B). BMMs deficient for the type I IFN receptor (IFNAR) – 
and thus unresponsive to the secreted type I IFNs – produce significantly reduced RANTES 
levels after infection with S. pneumoniae compared to wild-type BMMs.  
 
Fig. 10: Type I IFNs regulate the production of RANTES in an autocrine manner. (A, B) BMMs from wild-
type or IFNAR-/- mice were infected with D39 wild-type pneumococci (MOI 0.0025 or 0.025) for 16 h. (C, D) 
BMMs from wild-type or IRF3-/- mice were either infected with D39 wild-type pneumococci alone or 
stimulated with mIFNβ prior to and during the infection. RANTES mRNA levels were determined by 
quantitative RT-PCR. Secreted RANTES in the supernatant was quantified by ELISA. Data shown are 
mean ± SEM of at least three independent experiments carried out in triplicates. Statistical analysis was 
performed as described. * = p < 0.05, ** = p < 0.01, *** = p < 0.001. 
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In order to rule out that the difference in RANTES production was owing to a general defect 
in IFNAR-/- BMMs and not to type I IFN-related signaling, I sought to confirm this result in 
IRF3 -/- BMMs. As shown earlier, these macrophages were unable to up-regulate the 
production of type I IFNs after pneumococcal infection (Fig. 8 E, F). In accordance with the 
finding in IFNAR-/- BMMs, these cells also produced diminished levels of RANTES on the 
mRNA and protein level compared to their wild-type counterparts (Fig. 10C, D). Importantly, 
the defect of IRF3-/- cells in RANTES production after infection with S. pneumoniae could be 
rescued and even enhanced by the addition of exogenous IFNβ. Together, the results 
demonstrate that type I IFNs regulate RANTES production in macrophages in an autocrine 
manner. 
2.6 Type I IFNs produced by alveolar macrophages regulate the immune 
response of co-cultured alveolar epithelial cells in a paracrine 
manner 
In order to investigate the effects of type I IFNs in a more complex setting and with cells that 
are physiologically affected in pneumococcal pneumonia, a co-culture model of primary 
murine alveolar epithelial cells and alveolar macrophages was used (Fig. 11A). When the 
two cell types were infected separately with pneumococci, IFNβ was induced in alveolar 
macrophages but not in alveolar epithelial cells (Fig. 11B, C), which corroborates earlier 
findings. Next, alveolar epithelial cells from wild-type or IFNAR-/- mice were grown on 
transwell inserts and co-cultured with wild-type alveolar macrophages. Type I IFN produced 
by the macrophages would then be able to influence the gene expression in the co-cultured 
epithelial cells (Fig. 11A).  
After infection, ISGs such as ISG15, IRF7, and RANTES were induced in the co-cultured 
alveolar epithelial cells (Fig. 11D-F). Since epithelial cells do not produce type I IFNs 
themselves after S. pneumoniae infection (Fig. 11C), secreted type I IFNs from the 
macrophages might have positively influenced the expression of these genes in epithelial 
cells. This assumption is confirmed by the finding that co-cultured epithelial cells lacking the 
type I IFN receptor IFNAR showed significantly abrogated or reduced mRNA levels of these 
genes. Furthermore, RANTES concentrations were reduced in the supernatants of infected 
wild-type macrophages co-cultured with IFNAR-/- alveolar epithelial cells compared to the 
supernatants of co-cultured wild-type cells (Fig. 11G). This suggests that RANTES is type I 
IFN-dependently produced by alveolar epithelial cells in addition to the production by alveolar 
macrophages. Given that alveolar epithelial cells outnumber alveolar macrophages in the 
lung, the relevance of the type I IFN-dependent induction in epithelial cells is evident. Thus, 
type I IFNs produced by macrophages paracrinely regulate and shape the innate immune 
response in epithelial cells during infection with S. pneumoniae. 
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Fig. 11: Type I IFNs secreted by alveolar macrophages regulate the production of ISGs in co-cultured 
alveolar epithelial cells. (A) Schematic picture of the co-culture model. (B) Primary alveolar macrophages 
from C57BL/6 wild-type mice were infected with D39 (MOI 2.5) for 6 h. (C) Primary alveolar epithelial cells 
from C57BL/6 wild-type or IFNAR-/- mice were infected with D39 wild-type strain (MOI 2.5) for 6 h. (D-G) 
Alveolar macrophages from C57BL/6 wild-type mice were co-cultured with alveolar epithelial cells from 
wild-type or IFNAR-/- mice and subsequently infected with D39 wild-type strain (MOI 0.025) for 16 h. After 
infection, the epithelial cells were separated from the macrophages and mRNA expression was analyzed. 
mRNA expression of IFNβ, ISG15, IRF7, and RANTES was analyzed by quantitative RT-PCR. Secretion of 
RANTES into the supernatant of co-cultured cells was analyzed by ELISA. Data shown are mean ± SEM of 
at least three independent experiments carried out in duplicates. Statistical analysis was performed as 
described; ** = p < 0.01, *** = p < 0.001. 
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2.7 Effect of type I and type II IFNs on the progression of pneumococcal 
pneumonia 
After analyzing the pathway leading to type I IFN production and characterizing the effects of 
type I IFNs on the regulation of ISGs and RANTES in vitro, I studied the role of type I IFNs in 
an in vivo model of pneumococcal pneumonia. For this, IFNAR deficient mice were used, 
which are unable to respond to type I IFNs. Additionally, IFNGR knockout mice and 
IFNAR/IFNGR knockout mice were used in order to compare the effects of type I and II IFNs 
during pneumococcal pneumonia, and to examine potential synergistic effects of both IFN 
families. C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, IFNAR/IFNGR-/-) were infected 
intranasally with 1x106 cfu S. pneumoniae (NCTC7978; serotype 3). After 12 h or 48 h, the 
mice were sacrificed with subsequent analysis of the infection parameters and the immune 
response. The bacterial load in the broncho-alveolar lavage (BAL) of mice 12 h post infection 
(p.i.) remained equally high with no significant differences between the four genotypes (Fig. 
12A). 
 
Fig. 12: Type I IFNs negatively affect the bacterial replication but not the cell recruitment in the lung 
during pneumococcal pneumonia. C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, IFNAR/IFNGR-/-) were 
intranasally treated with PBS or infected with S. pneumoniae (1x10
6
 cfu, NCTC7978; serotype 3). (A, B) 
CFU in the BAL were analyzed at (A) 12 h or (B) 48 h p.i. (C) CFU in the blood were analyzed at 48 h p.i. (D) 
Cells in the BAL were counted and cell types were analyzed with the CytoSpin method. Sample size: PBS-
treated: n = 3, infected: n = 6-8. Data are shown as mean ± SEM. Statistical analysis was performed as 
described; ** = p < 0.01. 
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However, the mean bacterial load in IFNAR-/- and IFNAR/IFNGR-/- mice tended to be 
slightly lower compared to wild-type and IFNGR-/- mice. In the blood, no pneumococci could 
be detected at this time point (data not shown). At 48 h p.i., the bacterial numbers in both 
IFNAR-/- and IFNAR/IFNGR-/- mice were significantly reduced compared to the wild-type 
mice (Fig. 12B). Moreover, there was a trend of a diminished bacterial burden in the BAL 
when comparing wild-type and IFNGR-/- mice as well as IFNGR-/- and IFNAR/IFNGR-/- 
mice. This trend is, however, not statistically significant. At this time point, all mice showed 
positive blood cultures, demonstrating a spread of the pneumococci from the lung into the 
whole organism (Fig. 12C). A trend to reduced bacterial numbers in the blood of IFNAR-/- 
and IFNAR/IFNGR-/- mice could be observed that was, however, not statistically significant. 
These results show that type I IFNs negatively affect the clearance of S. pneumoniae from 
the lung. Moreover, type II IFN may also have a weak negative effect on the bacterial 
clearance as well, but not as pronounced as the effect of type I IFNs.  
The analysis of the cells in the BAL with the CytoSpin method revealed that all PBS-treated 
mice only have low numbers of macrophages present in the lavage fluid (Fig. 12D) The 
genotype did not influence the amount of cells present in the BAL of these uninfected mice. 
After infection, the amount of both polymorphonuclear leukocytes (PMNs) and, to some 
extent, of macrophages increased in a time-dependent manner. The recruitment of PMNs 
was similar in all mouse strains 12 h after infection. At 48 h p.i. the number of PMNs was 
slightly reduced in IFNAR-/- mice and more strongly diminished in IFNGR-/- and 
IFNAR/IFNGR-/- mice. The differences in the cell recruitment into the lung do not appear to 
be responsible for the enhanced clearance of the bacteria in these animals, since an 
increased recruitment of the cells did not correlate with an augmented clearance in these 
animals. In contrast, the enhanced clearance of bacteria in the lung of the mice at 48h p.i 
could have influenced the diminished recruitment of PMNs since a reduced bacterial burden 
might necessitate a weaker immune response. However, this does not explain, why IFNAR-/- 
mice with equally reduced bacterial numbers in the BAL to IFNAR/IFNGR-/- mice did not 
show an equally strong reduction in the recruited cells. Overall, it appears unlikely that 
effects of the type I IFNs or type II IFN on PMN recruitment into the lungs are responsible for 
the different bacterial clearance in the lung of the mice strains examined 
Analysing the body weight of the mice during the course of infection revealed that all mice 
had an initial loss of body weight by about 5% of their initial weight after intranasal 
inoculation with PBS or S. pneumoniae (Fig. 13A, B). This was likely due to the lack of food 
uptake during and after the narcosis at the time of infection. Moreover, while PBS-treated 
mice recovered fast and started gaining weight in the following time, infected mice (wild-type, 
IFNAR-/-, IFNGR-/-) continuously lost weight until 48 h p.i. (Fig. 13B). The weight loss was, 
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however, attenuated in IFNAR/IFNGR-/- mice with significantly less reduction of the body 
weight compared to wild-type mice. 
 
Fig. 13: Absence of type I and type II IFN signaling cooperatively reduces the loss of body weight and 
body temperature in mice with pneumococcal pneumoniae. C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, 
IFNAR/IFNGR-/-) were intranasally treated with PBS or infected with S. pneumoniae (1x10
6
 cfu, NCTC7978; 
serotype 3). (A, B) Body weight and (C, D) body temperature of the mice was measured every 12 h after 
PBS-treatment or infection. Sample size: PBS-treated: n = 3, infected: n = 6-8. Data are shown as mean ± 
SEM. Statistical analysis was performed as described; ** = p < 0.01, *** = p < 0.001. 
Another clinical parameter, the body temperature, also revealed a difference between the 
genotypes. While all PBS-treated mice kept a constant body temperature throughout the 
experiment (Fig. 13C), infected wild-type mice were unable to maintain their body 
temperature at the initial level and it kept dropping up to ~30°C at 48 h p.i. (Fig. 13D). In 
contrast, both IFNAR-/- and IFNGR-/- mice showed a significantly diminished temperature 
reduction compared to the wild-type mice at later time points. The IFNAR/IFNGR double 
deficient mice had an even slightly elevated temperature at 24 h and 36 h p.i. that remained 
significantly elevated throughout the experiment compared to wild-type mice. Thus, both the 
type I and type II IFN system negatively influence the sustainment of the body weight and 
temperature during pneumococcal pneumonia in mice. Taken together, these results suggest 
that both types of IFNs are somewhat detrimental for the mice during pneumococcal 
pneumonia. Mice double deficient for type I and II IFN signaling appear to be more resistant 
to pneumococcal pneumonia. 
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2.8 Effect of type I and type II IFNs on cytokines in the broncho-alveolar 
lavage during pneumococcal pneumonia 
Since type I IFNs, and to a minor degree type II IFN, seem to negatively influence the 
bacterial clearance from the lung and the resistance of mice towards pneumococcal 
pneumonia, the influence of these systems on the secretion of various cytokines and 
chemokines in the BAL was investigated.  
 
Fig. 14: Production of IFNβ and RANTES in the lung during pneumococcal pneumonia (A) C57BL/6 mice 
(wild-type) were infected with S. pneumoniae (1x10
6
 cfu, NCTC7978; serotype 3). After the indicated time-
points, the lungs were harvested, RNA was isolated and the expression of mIFNβ was analyzed with 
qPCR; n = 3 (B) C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, IFNAR/IFNGR-/-) were intranasally treated 
with PBS or infected with S. pneumoniae as described. RANTES concentrations in the BAL were 
determined by ELISA; PBS-animals: 12 h n = 2; 48 h n = 6; infected animals: n = 5-6. Data shown are mean 
±SEM. Statistical analysis was performed as described; *** = p < 0.001. 
First, it was confirmed that IFNβ was induced in the lung during pneumococcal pneumonia 
(Fig. 14A). The respective mRNA was detectable as early as 6 h p.i. and increased over time 
throughout the experiment. The production of RANTES, as shown in vitro in different 
infection models, was also detected in vivo in the BAL of infected mice (Fig. 14B). The 
overall induction at 12 h p.i. was still very low and a trend to reduced levels of RANTES was 
only observable in IFNAR/IFNGR-/- mice. However, at 48 h p.i., a sustained production of 
RANTES in wild-type mice and a slightly reduced production in IFNGR-/- mice could be 
detected. Both IFNAR-/- and IFNAR/IFNGR-/- mice showed an almost abrogated production 
of RANTES in the BAL. 
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Fig. 15: Type I IFN signaling promotes MCP-1 and IFNγ secretion into the BAL of during pneumococcal 
pneumonia in mice. C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, IFNAR/IFNGR-/-) were intranasally 
treated with PBS or infected with S. pneumoniae as previously described. Cytokines in the BAL were 
measured using the Bioplex assay. PBS-animals: n = 3-4, infected animals: n = 6-7. Data shown are mean 
±SEM. Statistical analysis was performed as described; * = p < 0.05, ** = p < 0.01. The dotted line 
represents the lower detection limit of this assay for the respective cytokine/chemokine. 
The concentrations of some cytokines seemed to be influenced by type I IFNs during 
pneumococcal pneumonia. IL-6 was moderately induced at 12 h p.i. and its levels were 
increased at 48 h p.i. (Fig. 15A). A trend of reduced IL-6 concentrations was observable in 
IFNGR-/- mice at 48 h p.i. and in IFNAR/IFNGR-/- mice at 12 h and 48 h p.i. Moreover, IFNγ 
concentrations in the BAL were very low at the early time point investigated, but were 
strongly increased at 48 h p.i. (Fig. 15B). Even at 12 h p.i., a reduction by trend was 
observable in the BAL of infected IFNAR-/- and IFNAR/IFNGR-/- mice. This reduction 
progressed to a strong and significant decrease of IFNγ at 48 h p.i. in these mouse strains. 
Another cytokine, TNFα, was strongly induced at 12 h p.i., whereas its concentrations were 
already declining at 48 h p.i. (Fig. 15 C). This decline was significantly enhanced in all 
knockout strains at this time point.  
The levels of the chemokine MCP-1 also showed differences in IFNAR-/- and IFNAR/IFNGR 
-/- mice compared to their wild-type counterparts. Increased levels of MCP-1 in wild-type 
mice were detectable already at 12 h p.i., which kept rising until the later time point (Fig. 
15D). The concentrations of MCP-1 in the BAL 12 h p.i. were reduced by trend in both 
IFNAR-/- and IFNGR-/- mice and significantly reduced in IFNAR/IFNGR-/- mice. At 48 h p.i., 
the MCP-1 levels in IFNGR-/- mice were only slightly lower than in wild-type mice, whereas a 
strong reduction could be seen in both IFNAR-/- and IFNAR/IFNGR-/- mice. 
 
 
48 
 
Fig. 16: Type I and type II IFN signaling does not influence the secretion many cytokines and chemokines 
into the BAL during pneumococcal pneumonia in mice. C57BL/6 mice (wild-type, IFNAR-/-, IFNGR-/-, 
IFNAR/IFNGR-/-) were intranasally treated with PBS or infected with S. pneumoniae as previously 
described. Cytokines in the BAL were measured using the Bioplex assay. PBS-animals: n = 3-4, infected 
animals: n = 6-7. Data shown are mean ±SEM. Statistical analysis was performed as described; * = p < 
0.05, ** = p < 0.01. The dotted line represents the lower detection limit of this assay for the respective 
cytokine/chemokine. 
Cytokines of the IL-1 family, IL-1α and IL-1β, were induced after infection, but did not 
continue to rise prominently throughout the time course (Fig. 16A, B). Their concentrations 
were reduced by trend in IFNGR-/- and IFNAR/IFNGR-/- mice at 12 h p.i. and significantly in 
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IFNAR/IFNGR-/- mice at 48 h after infection. IL-18, which is processed by inflammasomes 
like IL-1α and IL-1β, was below detection levels at both time points investigates (data not 
shown). 
Other chemokines that were reported to be important during pneumonia, e.g. KC and MIP-2, 
were induced upon infection with S. pneumoniae, but did not seem to be differentially 
regulated between the different mouse strains at 12h p.i. (Fig. 16C, D). However, a trend of 
reduced KC and MIP-2 levels in the BAL of IFNAR/IFNGR-/- mice 48 h p.i. was observable. 
Additionally, cytokines that play a role in T cell-mediated immunity were also investigated. IL-
17A was induced in wild-type mice after infection with S. pneumoniae, but only at 48 h after 
infection (Fig. 16E). This up-regulation was also observable in the single knockout mice, but 
not in the IFNAR/IFNGR-/- mice. Moreover, IL-22 was not induced in wild-type mice, but 
could be detected at 48 h p.i. in IFNAR-/- and IFNGR-/- mice (Fig. 16F). However, a negative 
regulation of IL-22 by both type I IFNs and type II IFN seems questionable, since no IL-22 
induction could be detected in double knockout mice. 
GM-CSF could be detected in the BAL as early as 12 h p.i. (Fig. 16G). While its 
concentration remained stable in wild-type mice, its initially strong induction at 12 h p.i. in 
IFNAR-/- mice was decreasing at the 48 h time point. GM-CSF remains reduced in IFNGR-/- 
and IFNAR/IFNGR-/- mice at both time points.  
In summary, the production of several pro-inflammatory cytokines and chemokines, including 
RANTES, MCP-1, and IFNγ, appears to be dependent on type I IFN signaling. However, it is 
important to consider that reduced concentrations of the investigated mediators at 48 h p.i. 
might also be due to the reduced bacterial load at this time points. A strong and early 
pneumococcal clearance in the lung could result in a weaker immune response at later time 
points due to a diminished bacterial burden, which might be reflected in the reduced cytokine 
and chemokine concentrations. Some mediators such as MCP-1 are already regulated as 
early as 12 h p.i. and show a significant reduction in IFNAR/IFNGR-/- mice compared to wild-
type mice. However, there is no immediately obvious relation between the IFN-mediated 
effects on the production of the cytokines and on their influence on the bacterial clearance 
from the lung. Further studies are required to resolve this conundrum. 
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3. Discussion 
Type I IFNs have historically been associated with the anti-viral defense and their role in 
bacterial infections has only begun to be characterized during the last years. Type I IFNs 
have been shown to regulate and fine-tune several immune pathways. The relative 
importance of these immune pathways for the host defense to different bacterial pathogens 
in different parts of the host organism might explain why type I IFNs can have either 
beneficial or detrimental effects on the outcome. Previous studies with S. pneumoniae only 
investigated the role of type I IFNs in vivo in models of sepsis, meningitis, or post-influenza 
pneumonia. The latter is different from primary pneumococcal pneumonia since the 
preceding virus infection induces very high amounts of IFNs. However, neither the pathway 
leading to type I IFN induction has been characterized, nor the role of type I IFNs in primary 
pneumococcal pneumonia. 
In this study, I could show that type I IFNs are induced after pneumococcal infection not only 
in vitro in human and murine macrophages (Fig. 3), but also in vivo in mouse lungs during 
pneumococcal pneumonia (Fig. 14). This induction is not strain specific since it could be 
detected after infection with strains of different serotypes (serotype 2, 3, and 4). The type I 
IFN response to S. pneumoniae was dependent on the phagocytic uptake of the bacteria and 
on the acidification of the phagosome (Fig. 5). The pneumococcal virulence factor PLY was 
required but not sufficient for stimulating the IFNβ induction. This suggests an indirect role of 
PLY in this pathway, e.g. in the delivery of the responsible pneumococcal PAMP to the host 
cell cytosol (Fig. 4). Several experimental results indicate that this PAMP might be 
pneumococcal DNA: (I) pneumococcal DNA appeared to be present in the host cell cytosol 
during infection as indicated by the activation of the AIM2 pathway (Fig. 6E); (II) S. 
pneumoniae DNA was capable of inducing type I IFNs when delivered in the cytosol of 
macrophages (Fig. 6C); (III) digestion of DNA by DNAses disables pneumococcal extracts 
from activating the production of type I IFNs (Fig. 6B). In the cytosol, the adaptor proteins 
STING and MyD88 as well as the transcription factor IRF-3 are involved in the induction of 
type I IFNs by S. pneumoniae (Fig. 7-9). TLR2, -3, -4, - 7-, and -9, NOD2, MAVS, DAI, and 
IFI16 are not required for the IFNα/β response. 
After induction, type I IFNs regulated RANTES production in S. pneumoniae-infected 
macrophages in an autocrine manner (Fig. 10). Type I IFNs produced by alveolar 
macrophages infected with pneumococci stimulated expression of different ISGs and the 
production of RANTES in neighboring lung epithelial cells (Fig. 11). In vivo, the overall effect 
of type I IFNs in pneumococcal pneumonia was detrimental. Mice deficient in IFNAR were 
able to control pneumococcal infection in the lung better than wild-type mice (Fig. 12), and 
mice deficient for both type I and II IFN signaling had a diminished reduction of the body 
weight and temperature compared to wild-type and singe knock-out mice (Fig. 13). Finally, 
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type I and II IFNs contributed to the regulation of some important inflammatory mediators 
during pneumococcal pneumonia (Fig. 14-16). The results of this study can be combined in a 
model that is displayed in Fig. 17.  
 
Fig. 17: Model of the induction and effects of type I IFN induction in pneumococcal infection in the lung. 
S. pneumoniae is phagocytosed by alveolar macrophages and digested in the endosome. Pneumococcal 
PLY damages the endosomal membrane which leads to the release of PAMPs – probably S. pneumoniae 
DNA – into the cytosol. This triggers one or several pathways involving STING, MyD88, and IRF3 and 
leads to the production and secretion of type I IFNs. These bind to IFNAR on both alveolar macrophages 
and on alveolar epithelial cells and result in the induction of several ISGs, including IRF7, ISG15, 
RANTES, MCP-1, and IFNγ. In vivo, type I IFN signaling causes an enhanced susceptibility of the host to 
pneumococcal pneumonia. 
3.1 Pneumococcal factors required for the induction of type I IFNs 
3.1.1 Pneumolysin 
Pneumolysin is an important virulence factor of S. pneumoniae. It remains controversial if 
PLY is actively secreted by S. pneumoniae or if it is only released after pneumococcal (auto-) 
lysis (Marriott, et al., 2008). After secretion/release from the bacteria, higher doses of PLY 
form pores in target membranes which leads to cell damage and ultimately cell death. Lower 
doses of PLY are able to inhibit the cilliary action of epithelial cells, impair the respiratory 
burst of phagocytic cells, and activate both the complement system and the 
cytokine/chemokine production (Hirst, et al., 2008; Maus, et al., 2004; Rubins, et al., 1996; 
Witzenrath, et al., 2006). In addition, PLY activates the NLRP3 inflammasome (Fang, et al., 
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2011; Hoegen, et al., 2011; McNeela, et al., 2010; Witzenrath, et al., 2011) and has been 
suggested to interact with and activate TLR4 (Malley, et al., 2003; Srivastava, et al., 2005). 
The presented data reveal a crucial role of PLY in the induction of type I IFNs after 
pneumococcal infection (Fig. 3A, C, F). Pneumococcal strains deficient in PLY did not induce 
IFNβ. Since TLR4 is dispensable for the type I IFN response (Fig. 7A), PLY must either be 
sensed via a different PRR or could contribute to the IFNα/β induction in another way. 
Treatment of macrophages with recombinant PLY in the absence of S. pneumoniae was not 
sufficient for IFNβ induction (Fig. 4A). Thus, PLY might stimulate the type I IFN response 
indirectly through its pore-forming properties.  
In parallel to my findings, Parker et al. reported that the type I IFN induction in response to S. 
pneumoniae infection of murine nasopharyngeal epithelial cells in vitro, and during 
nasopharyngeal colonization in vivo is also dependent on PLY (Parker, et al., 2011). 
Moreover, it was reported that PLY alone did not lead to the induction of the IFNα/β 
response. Interestingly, in this publication a weak type I IFN response after incubation of 
cells together with recombinant PLY and pneumococcal lysates was reported. However, this 
response was absent when the cells were incubated with pneumococcal lysates and a non-
pore-forming PLY. This substantiates the hypothesis that PLY itself is not directly sensed but 
that it mediates the transfer of pneumococcal PAMPs into the cytosol by forming pores. 
Additionally, another study on the type I IFN induction by group B streptococci found that 
pore-forming toxins were also required in this setting (Charrel-Dennis, et al., 2008). It was 
suggested that these toxins form pores in the phagolysosomal membrane, which 
subsequently allows the microbial PAMPs to gain access to the cytosol, where they are 
sensed by PRRs leading to the IFNα/β induction. 
Thus, my results as well as the above mentioned studies suggest that the type I IFN 
response to streptococci, such as S. pneumoniae and group B streptococcus, is dependent 
on pore-forming toxins that allow microbial PAMPs to access the cytosol and stimulate host 
cell responses. 
3.1.2 DNA 
Since the above shown findings indicate that the role of PLY in the induction of type I IFNs 
constitutes rather mediating the transfer of a pneumococcal PAMP into the cytosol than 
being directly recognized itself, I concluded that at least one other pneumococcal PAMP 
must be required for this response. I was able to show that S. pneumoniae DNA is generally 
capable of inducing type I IFNs after cytosolic delivery into the cell (Fig. 6C). Moreover, 
pneumococcal extracts lost their IFNβ-inducing capabilities when they were digested with 
DNase before transfection into the cytosol (Fig. 6B). These experiments demonstrate that S. 
pneumoniae DNA is generally capable to induce type I IFNs. However, this does not prove 
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that pneumococcal DNA does actually access the cytosol during infection with S. 
pneumoniae. While direct imaging attempts of pneumococcal DNA in the cytosol using 
confocal microscopy or Fluorescence in situ hybridization (FISH) were either unsuccessful or 
not applicable, a more indirect approach was chosen.  
AIM2 is a cytosolic DNA sensor that forms the AIM2 inflammasome together with ASC and 
caspase-1, which regulates the production of cytokines, e.g. IL-1β. Since the RNAi-mediated 
knockdown of AIM2 led to a reduction in IL-1β secretion after infection with S. pneumoniae 
(Fig. 6E), it can be concluded that DNA is indeed sensed in the cytosol during pneumococcal 
infection. However, since AIM2 (as well as other cytosolic DNA sensors) can be activated by 
both microbial and endogenous DNA, the origin of the cytosolic DNA activating AIM2 during 
pneumococcal infection could not be unambiguously determined. Thus, it is also conceivable 
that cellular DNA would be sensed as an indirect result of cell damage after infection, 
although the sensing of pneumococcal DNA appears more likely. In order to identify the 
origin of the DNA, I attempted to non-covalently label pneumococcal DNA with fluorescent 
dyes, e.g. DAPI and Syto®82 Orange Fluorescent Nucleic Acid Stain before infection. During 
infection, however, these dyes dissociated from the pneumococcal DNA which led to an 
unspecific staining of cellular nucleic acids (data not shown). To prevent this unspecific 
staining, I sought to detect pneumococcal DNA in the cytosol by using FISH. The rationale 
was to use probes that are covalently labeled with a fluorescent dye which would interact 
with S. pneumoniae DNA in a sequence-specific manner. This way, it would be possible to 
obtain a specific signal, which could validate this model. Unfortunately, an experienced 
collaboration partner advised against this approach with the statement that the FISH method 
would not be sensitive enough to detect trace amounts of pneumococcal DNA in the cytosol. 
For future experiments, I suggest to covalently label S. pneumoniae DNA with the thymidine 
analog 5’-bromo-2’-deoxyuridine (BrdU) prior to infection. The covalent incorporation into the 
DNA should prevent the dissociation of the dye into the cytosol and thus any unspecific 
labeling. BrdU-labeled pneumococcal DNA could then be detected with a specific antibody. 
This would be an elegant approach to investigate the origin of the DNA that is sensed in the 
cytosol upon infection with S. pneumoniae. 
In agreement with my results, earlier studies demonstrated that the cytosolic delivery of DNA 
leads to the induction of type I IFNs (Stetson and Medzhitov, 2006). The involvement of 
DNA-sensing pathways was also implied to contribute to the induction of IFNα/β after 
infection with L. monocytogenes and L. pneumophila as well as group A and group B 
streptococci (Charrel-Dennis, et al., 2008; Gratz, et al., 2011; Lippmann, et al., 2011; Stetson 
and Medzhitov, 2006). Similarly to my results, some studies were able to show that the type I 
IFN-inducing capabilities of bacterial extracts upon cytosolic delivery could be diminished or 
even abolished by a pre-treatment with DNase prior to transfection (Charrel-Dennis, et al., 
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2008; Lippmann, et al., 2011; Stetson and Medzhitov, 2006). In accordance to my data, 
cytosolic proteins involved in DNA recognition, e.g. STING, were shown to be involved in the 
induction of IFNα/β during infection (Charrel-Dennis, et al., 2008; Lippmann, et al., 2011). 
However, RNA was also suggested as the IFNα/β-inducing PAMP in infections with 
Legionella and group A streptococci (Gratz, et al., 2011; Monroe, et al., 2009). Thus the 
exact nature of the type I IFN-inducing PAMP is not absolutely certain. In agreement with my 
results, the authors of the recently published paper about the type I IFN response after 
pneumococcal infection also showed that pneumococcal DNA is able to induce IFNα/β and 
that pneumococcal extracts lose their ability to elicit type I IFNs after DNase treatment 
(Parker, et al., 2011). However, additional studies are required to further examine the 
mechanisms and role of DNA sensing during S. pneumoniae infection. Moreover, possible 
contributions of other microbial structures or molecules, such as RNA or cyclic di-nucleotides 
(Burdette, et al., 2011; Mills, et al., 2011; Woodward, et al., 2010) should be examined in 
upcoming projects. 
3.2 Cellular factors required for the induction of type I IFNs 
3.2.1 Phagocytosis 
Type I IFNs are induced after infection with S. pneumoniae in macrophages, but not in 
epithelial cells (Fig. 3). Moreover, when the phagocytic uptake of macrophages is inhibited 
with cytochalasin D, the IFNα/β induction is also blocked (Fig. 5A, C). This indicates that the 
phagocytosis of pneumococci is required for mounting the type I IFN response and that only 
cells capable of phagocytosis are able to produce type I IFNs. More supporting evidence for 
this model stems from the observation that in vitro the magnitude of the IFNβ induction 
correlates with the magnitude of the phagocytic uptake of strains of different serotypes (Fig. 
3). TIGR4 pneumococci (serotype 4) are not as well phagocytosed as D39 pneumococci 
(serotype 2) and do also induce type I IFNs to a much weaker degree. Pneumococcal 
serotypes differ in the type of the capsule, which has anti-phagocytic properties. Moreover, 
the magnitudes of phagocytosis and IFNα/β induction after infection with the capsule-
deficient pneumococcal strains, D39 Δcps and TIGR4 Δcps, are similar. This indicates that 
the capsule influences both the phagocytosis and the type I IFN response. The relative low 
amounts of type I IFNs induced by TIGR4 wild-type pneumococci in vitro, however, do not 
necessarily imply that the here described pathway might be without importance in S. 
pneumoniae infections with serotype 4 strains. In vivo, the phagocytosis rates of these 
strains might be much higher since components of the humoral immune response 
(complement, C-reactive protein) bind to S. pneumoniae and promote its phagocytosis 
(Yuste, et al., 2008). Thus, additional in vivo experiments should be performed to determine 
the extent of phagocytosis and the amount of type I IFN induction of different serotypes. 
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Moreover, it would be interesting to investigate if the nonetheless varying magnitudes of type 
I IFN induction would lead to an altered disease progression, which could be clinically 
relevant.  
The above shown data strongly supports the hypothesis that only cells capable of 
phagocytosis can induce type I IFNs. In contrast, the study of Parker et al. suggested that 
type I IFNs are also produced in murine nasal epithelial cells (Parker, et al., 2011). Moreover, 
it was reported that this induction is independent of the phagocytic uptake since it was not 
affected by cytochalasin D in a concentration 20-fold higher than the one used in this study. 
A reason for this divergence could be that Parker et al. used primary polarized epithelial cells 
from mouse septa. Since it was not mentioned if the purity of the isolated cells was 
determined, it is possible that different cell types in the primary cell culture would have led to 
the published results. Additionally, the pneumococcal dose used for infection was about 500-
fold higher than in this study and the observed magnitude of type I IFN induction was only 
about 10-fold versus about 1000-fold in this study. Thus, the massive amount of bacteria 
might have led to this weak IFNβ induction also in a non-phagocytosing cell type. In 
accordance with my results, other studies with group B streptococci and L. pneumophila 
reported as well that phagocytosis of bacteria is required for the induction of type I IFNs 
(Charrel-Dennis, et al., 2008; Lippmann, et al., 2011). 
3.2.2 Acidification 
Additionally to the phagocytosis of the pneumococci, the acidification of the endosomal 
compartment is also required for the type I IFN response to S. pneumoniae. The incubation 
of cells with different acidification inhibitors prior to infection led to a strongly diminished IFNβ 
induction (Fig. 5B, D). These results are in accordance with earlier studies with L. 
pneumophila and group B streptococci that also report a dependency of the type I IFN 
response on the acidification of the endosomes (Charrel-Dennis, et al., 2008; Lippmann, et 
al., 2011). These observations can be integrated into the following model: S. pneumoniae is 
phagocytosed by macrophages and destroyed in the endosomal compartment. Thus, 
pneumococcal components, such as DNA, are released from the bacteria. Subsequently, 
these could access the cytosol (possibly via PLY) and elicit the type I IFN response.  
3.2.3 STING and STING-dependent signaling pathways 
RNAi experiments could clearly demonstrate a role of STING in the induction of type I IFNs 
during infection with S. pneumoniae (Fig. 9A-C). STING has been characterized as a 
receptor of cyclic di-GMP and as an adaptor protein for cytosolic PRRs that sense DNA 
(Burdette, et al., 2011; Ishikawa, et al., 2009; Unterholzner, et al., 2010; Zhang, et al., 2011). 
Mice deficient in STING were more susceptible to infection with herpes simplex virus 
(Ishikawa, et al., 2009). Moreover, STING was essential for the type I IFN response after 
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infection with L. monocytogenes (Ishikawa, et al., 2009; Jin, et al., 2011; Sauer, et al., 2011), 
F. tularensis (Jin, et al., 2011), and L. pneumophila (Lippmann, et al., 2011). However, even 
though a requirement of STING in the early induction of type I IFNs in vivo after infection with 
L. monocytogenes and F. tularensis could be demonstrated, STING-/- mice had a normal 
late type I IFN response and comparable bacterial burdens in the spleen 48 h and 72 h p.i. 
compared to wild-type mice (Jin, et al., 2011; Sauer, et al., 2011). This indicates that other 
cellular pathways exist that mediate a delayed IFNα/β induction. Since the above shown 
results demonstrate a clear involvement of STING in the early induction of type I IFNs 6 h 
p.i., it would be interesting to investigate the requirement of STING for the type I IFN 
response in vivo after infection with S. pneumoniae.  
In accordance with the publications that describe STING to be an adaptor protein for DNA-
sensing pathways, my experimental data also implicate that DNA sensing could be involved 
in the type I IFN response to S. pneumoniae (Fig. 6). Thus, I attempted to identify cytosolic 
PRRs that have been shown to sense DNA and to signal via STING. DAI was the first 
receptor to be implicated in the recognition of DNA in the cytosol in vitro. However, 
macrophages or mouse embryonic fibroblasts from DAI knockout mice were still capable of 
inducing IFNα/β after transfection of DNA or after infection with DNA virus (Ishii, et al., 2008). 
In accordance, my RNAi experiments did not argue for a non-redundant role of DAI in the 
type I IFN response after infection with S. pneumoniae (Fig. 9D, E). At best, a slight 
reduction of the IFNβ mRNA induction could be observed. However the amount of this 
reduction was negligible compared to the magnitude of the still existing IFNβ response. A 
possible explanation for this could be that the siRNA-mediated knockdown of DAI was not 
strong enough in order to show differences in the type I IFN response. One could use DAI-/- 
macrophages in order to confirm this finding. However, since DAI was not found to be a non-
redundant DNA sensor in different infection models (Ishii, et al., 2008; Lippmann, et al., 
2008), a prominent role in the detection of S. pneumoniae seems to be less likely. Still, it is 
possible that DAI is one of several redundant DNA-sensing PRRs, which sense 
pneumococcal infection. In contrast to my findings, Parker et al. recently stated an 
involvement of DAI in the recognition of pneumococcal DNA (Parker, et al., 2011). However, 
this was possibly an overstatement, since a substantially reduced type I IFN response in 
DAI-/- BMMs could only be observed after transfection of purified pneumococcal DNA, which 
does not reflect an infection with viable bacteria. In contrast, the difference in IFNα/β levels of 
wild-type and DAI -/- BMMs after infection with S. pneumoniae was very low and the values 
had high standard deviations. Overall, DAI does not appear to play an important, non-
redundant role in the induction of type I IFNs after pneumococcal infection. 
IFI16, a member of the PYHIN protein family, was shown to mediate the induction of IFNα/β 
after transfection of DNA and after infection with DNA viruses (Unterholzner, et al., 2010). 
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Apart from its role in the type I IFN response, IFI16 has been indicated to have direct antiviral 
properties (Gariano, et al., 2012) and to regulate the inflammasome-dependent IL-1β 
production on different levels (Kerur, et al., 2011; Veeranki, et al., 2011). The siRNA-
mediated knockdown of IFI16 with three different siRNAs, however, did not lead to a reduced 
IFNβ response in BMMs after infection with S. pneumoniae (Fig. 9F, G). As in the case of 
DAI, the knockdown might not have been efficient enough to yield a phenotype in the type I 
IFN response. Thus, the confirmation of this result in IFI16-/- BMMs is recommended. 
However, the above discussed data do not argue for a non-redundant role of IFI16 in the 
type I IFN response to infection with S. pneumoniae.  
In addition to DAI and IFI16, I started to examine, the role of other recently described PRRs 
that were implied to sense DNA. DDX41 belongs to the DEXD/c-family of helicases and was 
recently described to bind to both B-form and Z-form DNA and to subsequently induce type I 
IFNs in myeloid DCs (Zhang, et al., 2011). DDX41 recruits STING, which leads to the 
activation of the transcription factors IRF-3 and NF-κB. During infection of murine of human 
macrophages with DNA viruses (herpes simplex virus or vaccinia virus) or with the gram-
positive bacterium L. monocytogenes, DDX41 was required for the production of type I IFNs. 
Thus, I investigated the role of this helicase using an RNAi approach. However, experiments 
with different siRNAs in BMMs were so far unsuccessful in producing a sufficient knockdown 
of DDX41 in BMMs (data not shown), which made the examination of the role of this protein 
in the S. pneumoniae-induced type I IFN response impossible. Thus, improved RNAi 
techniques (such as more efficient siRNAs or short hairpin RNAs) or DDX41-/- BMMs should 
be employed to answer this question. 
Although the knockdown of putative DNA sensors, such as DAI and IFI16, did not show a 
phenotype, they might still play a role in the type I IFN induction during pneumococcal 
infection. It is possible that these pathways play a redundant role in triggering the IFNα/β 
induction and that only the simultaneous inhibition of several receptors systems would result 
in an impairment of the type I IFN response to S. pneumoniae. The weak attenuation of the 
IFNβ response after siRNA-mediated knockdown of DAI – described both in this study and 
by Parker et al. – could be an indicator for this and could possibly be enhanced by a 
simultaneous knockdown of further DNA sensors. In this case, the detection of 
pneumococcal DNA and the stimulation of type I IFN production would be dependent on 
additional yet-to-be-identified cytosolic DNA sensors that also signal via STING 
Additionally to being involved in the signal cascade of DNA-sensing pathways, cyclic di-
nucleotides, such as cyclic di-GMP and cyclic di-AMP have both been shown to induce type I 
IFNs via STING (Burdette, et al., 2011; Woodward, et al., 2010). Moreover, STING was 
recently described to be a direct sensor of cyclic di-GMP (Burdette, et al., 2011). Thus, 
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instead of being activated by DNA as suggested above, cyclic di-nucleotides could also 
contribute to the type I IFN induction via STING during pneumococcal infection. These 
molecules are prevalent second messengers in bacteria and the genetic information for the 
di-adenylate cyclase domain, which is responsible for the production of cyclic di-AMP, has 
been shown to be present in Streptococci (Romling, 2008). Thus, it would be interesting to 
investigate if cyclic di-nucleotides also play a role in the host defense in general and 
especially in the type I IFN response to S. pneumoniae. 
3.2.4 MyD88 and MyD88-dependent signaling pathways 
The type I IFN response to S. pneumoniae was not only dependent on STING, but also on 
the adaptor molecule MyD88 (Fig. 7F). MyD88 is the central adaptor molecule of most TLRs. 
However, the only TLRs that are known to induce type I IFNs via MyD88 are TLR7, -8, and -
9 (Kawai, et al., 2004), whereas TLR3 and -4 use the adaptor TRIF to trigger IFNα/β 
induction. The type I IFN response to S. pneumoniae was, however, unaltered in 
TLR2/3/4/7/9-/- BMMs compared to wild-type cells (Fig. 7A). Thus, other receptors upstream 
of MyD88 might be involved in the IFNα/β-induction after infection with S. pneumoniae. In the 
case of TLRs, this leaves TLR8 to be the only remaining TLR could be involved in the 
MyD88-dependent type I IFN response. However, murine TLR8 was long regarded to be 
non-functional (Jurk, et al., 2002). Surprisingly, recent publications implicate a role of this 
TLR in the negative regulation of TLR7 (Demaria, et al., 2010), in neuronal function (Ma, et 
al., 2007), and in the recognition of the dsDNA of the vaccinia virus (Martinez, et al., 2010). 
Although a contribution of TLR8 to the type I IFN response to S. pneumoniae infection does 
not seem to be very likely, future studies with TLR8-/- BMMs should be performed to rule out 
a possible involvement of this TLR in the type I IFN response to S. pneumoniae.  
Apart from relaying signals from the type I IFN-inducing TLRs, MyD88 was also shown to be 
involved in the type I IFN induction mediated by DExD/H helicases. In plasmacytoid DCs, the 
helicases DHX9 and DHX36 were shown to recognize different CpG-DNA motifs and to 
signal through the adaptor protein MyD88 (Kim, et al., 2010). Additionally, both helicases 
were also involved in the recognition of RNA (Zhang, et al., 2011; Zhang, et al., 2011). After 
stimulation with DNA, the activation of DHX9 led to the induction of NF-κB and to the 
production of TNFα and IL-6, whereas the activation of DHX36 resulted in the production of 
IFNα via the transcription factor IRF7 (Kim, et al., 2010). Both helicases were important in 
mediating cytokine responses in plasmacytoid DCs after infection with the DNA virus herpes 
simplex virus. Considering the role of DHX9 and DHX36 in sensing cytosolic DNA and in 
activating MyD88, these helicases are also possible candidates to be involved in the 
recognition of S. pneumoniae. Unfortunately, experiments with two different siRNAs against 
DHX36 could only produce a knockdown of 50% on the mRNA level and an impaired 
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induction of IFNβ after pneumococcal infection was not observable (data not shown). Thus, 
improved RNAi methods such as shRNA or knockout cells are required in order to obtain an 
adequate experimental system that allows to investigate the role of DHX36 in the type I IFN 
response triggered by S. pneumoniae. 
Even though the involvement of the cytosolic DNA sensing pathways in the type I IFN 
response, which engage MyD88 and IRF3/7, needs to be further elucidated, IRF3/7-
independent pathways could also be involved. Earlier studies showed that the promoter of 
the IFNβ gene not only contains binding sites for IRF3/7, but also for the transcription factors 
NF-κB (Thanos and Maniatis, 1992) and ATF2/c-jun, also known as AP-1 (Du, et al., 1993). 
The activation of all transcription factors and their coordinated binding to the promoter region 
as an enhancer complex is required for a strong transcription of the IFNβ gene. Thus, the 
contribution of MyD88-dependent signaling could also be directed via the TLR-/MyD88-
dependent activation of NF-κB, which has been extensively described to occur during 
infection with S. pneumoniae (Mogensen, et al., 2006). 
3.2.5 Other cytosolic DNA sensing pathways 
The involvement of the RNA polymerase III/RIG-I pathway in inducing type I IFNs after 
pneumococcal infection was examined by investigating MAVS-/- BMMs. MAVS is the adaptor 
molecule of RIG-I. Thus, any RNA-intermediate produced by RNA polymerase III and 
subsequently sensed by RIG-I would require MAVS in order to stimulate the induction of type 
I IFNs. Pneumococcal infection of both wild-type and MAVS-/- BMMs led, however, to a 
comparable IFNβ induction in those cells (Fig. 8C). Thus, a non-redundant contribution of 
this pathway to the type I IFN response can be excluded. 
Another DNA-sensing PRR that can contribute to the IFNα/β induction is LRRFIP1 (Yang, et 
al., 2010). LRRFIP1 (leucine rich repeat (in FLII) interacting protein 1) is implicated in binding 
both poly dA:dT and poly dG:dC DNA, which stimulates the IRF3-mediated production of 
type I IFNs via β-catenin and CBP/p300 histone acyltransferases. This pathway was shown 
to play a role in the type I IFN induction after infection with L. monocytogenes and the 
vesicular stomatitis virus (Yang, et al., 2010). siRNAs targeting LRRFIP1 did, however, not 
alter the S. pneumoniae-stimulated induction of IFNβ in BMMs compared to cells that were 
transfected with unspecific siRNA (data not shown). Since the knockdown on the mRNA level 
was again only around 60%, improved RNAi techniques should be used in future 
experiments to comprehensively investigate the involvement of LRRFIP1 in this response. 
3.2.6 NOD2 
Additionally to its stimulating effect on NF-κB, a recent publication recently suggested that 
NOD2 also contributes to the production of type I IFNs in mice during the nasopharyngeal 
colonization with S. pneumoniae (Nakamura, et al., 2011). Moreover, NOD2 was suggested 
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to interact with viral ssRNA, which resulted in a MAVS-dependent induction of IFNβ (Sabbah, 
et al., 2009). However, both my data and also Parker et al. did not reveal a contribution of 
NOD2 to the type I IFN response after pneumococcal infection in vitro (Fig. 8A) and in vivo 
(Parker, et al., 2011). Moreover, I was able to show that the observed IFNβ-induction was 
independent of MAVS (Fig. 8C). Thus, the ssRNA-sensing pathway can be excluded in 
detecting S. pneumoniae infection. Differences in the contribution of NOD2 to the type I IFN 
response in these studies could be owing to the use of different S. pneumoniae strains. 
While the studies demonstrating a NOD2-independent type I IFN response used D39 
pneumococci (serotype 2) (see above and (Parker, et al., 2011)), the study that showed an 
involvement of NOD2 used the P1121 strain (serotype 23F), which does not cause an 
invasive infection in mice (Nakamura, et al., 2011). Future studies should investigate an 
involvement of the invasiveness and other strain specificities in the pathway of type I IFN 
induction. 
3.3 Auto- and paracrine effects of type I IFNs on the immune response 
Type I IFNs were produced by macrophages, but not by epithelial cells after infection with S. 
pneumoniae. The secreted type I IFNs not only autocrinely activated the expression of 
RANTES in macrophages, but also stimulated epithelial cells in a paracrine manner. This 
leads to the model that in pneumococcal pneumonia, type I IFNs are induced by sentinel 
alveolar macrophages, which subsequently regulate the innate immune response of the 
abundantly existing alveolar epithelial cells. 
3.3.1 RANTES 
RANTES is a chemokine with many physiological functions. It was shown to be a strong 
chemoattractant for T cells, DCs, eosinophils, NK cells, mast cells and basophils (Levy, 
2009). RANTES can be produced by various cells, including macrophages, endothelial, and 
epithelial cells. After secretion, it can bind to the chemokine receptors CCR1, CCR3, CCR4, 
and CCR5. This induces leukocyte activation and chemotaxis to the site of infection (Appay 
and Rowland-Jones, 2001). 
In a mouse model of pneumococcal colonization, RANTES was highly expressed in the 
nasopharyngeal-associated lymphoid tissue as well as in the cervical lymphnodes 
(Palaniappan, et al., 2006). It positively regulated the production of cytokines such as IL-4, 
IFNγ, and IL-12p40. A blockade of RANTES with a specific antibody led to a reduced 
recruitment of leukocytes as well as to an enhanced progression of nasopharyngeal carriage 
of S. pneumoniae to invasive and potentially lethal pneumonia (Palaniappan, et al., 2006). 
Moreover, in a model of pneumococcal pneumonia, RANTES was shown to contribute to the 
recruitment of macrophages into the alveoli together with the chemokines MCP-1 and MIP-
1α (Fillion, et al., 2001). 
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I was able to show that RANTES was induced after pneumococcal infection in macrophages 
and co-cultured epithelial cells (Fig. 10, 11F, G). Since the RANTES promoter contains NF-
κB as well as ISRE binding sites (Casola, et al., 2002), both the type I IFN response as well 
as TLRs and NLRs are expected to contribute to the production of this chemokine. Indeed, 
the RANTES induction in both macrophages and epithelial cells was partly dependent on 
type I IFNs. Interestingly, the secretion of RANTES into the supernatants of wild-type 
macrophages co-cultured with IFNAR-/- alveolar epithelial cells was still significantly 
reduced. This indicates that the epithelial cells substantially contribute to the production of 
RANTES in this setting. Moreover, these findings corroborate the hypothesis that 
macrophages act as sentinels that regulate the chemokine production in neighboring 
epithelial cells after infection. 
In vivo, the production of RANTES in the BAL was robust at 48 h p.i. in wild-type mice (Fig. 
14). IFNAR-/- mice showed almost absent RANTES concentrations in the BAL. Moreover, 
IFNGR-/- mice also had significantly reduced RANTES levels in the BAL, but the decrease 
was not as big as in the IFNAR-/- mice. This might reflect the supporting function of type II 
IFN, which is able to activate not only GAS, but also ISRE promoter sites to a weaker extent. 
However, a part of this effect might be due to the reduced bacterial load in the lungs at this 
time point, which is also discussed later (see 3.4.1). A lower pneumococcal concentration in 
the lung could also relate to a lower expression of target genes. At an earlier time point (12 h 
p.i.), the bacterial load was rather similar between the genotypes, and the induction of 
RANTES was still very low. Still, IFNAR/IFNGR-/- mice had lower RANTES levels in the BAL, 
which indicates that a co-operative effect of type I and type II IFNs could promote the 
production of this chemokine in vivo.  
3.3.2 ISGs 
Apart from RANTES, other ISGs are activated by type I IFNs in the alveolar epithelial cells. I 
could show that type I IFNs produced by macrophages regulate the ISGs IRF7 and ISG15 in 
co-cultured epithelial cells (Fig. 11D, E). Both are known to be induced by type I IFNs, which 
substantiates the suggested model that IFNα/β secreted by macrophages also regulates 
ISGs in epithelial cells, which are not capable of IFNα/β production themselves. Since IRF7 
is known to enhance and sustain the production of type I IFNs and possibly ISGs at later time 
points (Levy, et al., 2002), the finding that S. pneumoniae-infected macrophages regulate the 
IRF7 expression in neighboring epithelial cells might be relevant for the expression of ISGs 
important for the host defense against pneumococci. Future studies should identify all the 
ISGs that are activated by type I and type II IFNs and should consequently investigate their 
role in the immune response to S. pneumoniae. 
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3.4 Interferons in pneumococcal pneumonia 
The role of type I IFNs in bacterial infections has been investigated during the last years in 
different infection models. They were shown to have protective effects for the host in a 
murine model of L. pneumophila pneumonia (Lippmann, et al., 2011) as well as in systemic 
infection with group B streptococcus and E. coli (Mancuso, et al., 2007). Protective effects of 
type I IFNs include the induction of anti-microbial ISGs, including iNOS, IDO, and p47 
GTPases, which inhibit the intracellular replication of the bacteria (Daubener and MacKenzie, 
1999; Howard, 2008; Plumlee, et al., 2009). Moreover, IFNα/β strongly reduced the invasion 
of Salmonella and Shigella into epithelial cells (Bukholm, et al., 1984; Niesel, et al., 1986). 
Type I IFNs also regulate the production of cytokines. They were shown to stimulate the 
production of IFNγ during infection with S. typhimurium (Freudenberg, et al., 2002) and L. 
monocytogenes (Carrero, et al., 2006). Additionally, type I IFNs reduced the surface 
expression of the IFNγ receptor (IFNGR) on immune cells, such as macrophages and 
dendritic cells (Rayamajhi, et al., 2010), which rendered the cells less responsive to 
activation by IFNγ and thus modulated the immune response. Additionally to IFNγ, the 
cytokine IL-1β is also regulated by type I IFNs on different levels. Via the induction of the 
anti-inflammatory cytokine IL-10, IFNα/β inhibits the mRNA expression of the precursor pro-
IL-1β (Guarda, et al., 2011; Novikov, et al., 2011). On the other hand, type I IFNs appeared 
to inhibit some inflammasomes, e.g. the NLRP1 and NLRP3 inflammasomes (Guarda, et al., 
2011), whereas they induced others, e.g. the AIM2 inflammasome (Choubey, et al., 2010; 
Fernandes-Alnemri, et al., 2010). Thus, depending on the type of infection type I IFNs can 
have both inhibiting and promoting effects on IL-1β. 
In contrast to the protective effects in the above mentioned infection models, IFNα/β can also 
have negative effects in infections with other pathogens, e.g. L. monocytogenes or M. 
tuberculosis. In these infection models, the induction of type I IFNs was show to be 
detrimental for the host (O'Connell, et al., 2004; Stanley, et al., 2007). After systemic 
infection with L. monocytogenes, mice deficient in the type I IFN receptor had reduced 
bacterial loads in liver and spleen as well as a strongly enhanced survival (O'Connell, et al., 
2004). The enhanced susceptibility of wild-type mice compared to IFNAR-/- mice was 
attributed to the ability of type I IFNs to induce apoptosis in macrophages and lymphocytes 
during Listeria infection (Carrero, et al., 2004; Stockinger, et al., 2002). In viral infection, type 
I IFN-mediated apoptosis of infected host cells could limit the proliferation of the virus. 
However, during infection with L. monocytogenes, this mechanism promotes the death of 
important immune cells and is detrimental to the host (Carrero and Unanue, 2012). Thus the 
overall effect of type I IFNs on the host defense in vivo varies in different infection models. 
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In pneumococcal disease, the investigation of the role of type I IFNs in different infection 
models has yielded conflicting results. It was reported that IFNα/β signaling is beneficial to 
the host in a model of pneumococcal sepsis and meningitis (Mancuso, et al., 2007). 
Moreover, a paper published in parallel to this study indicated a protective role of type I IFNs 
in pneumococcal colonization (Parker, et al., 2011). However, other reports indicated a 
detrimental effect of type I IFNs in pneumococcal colonization and pneumonia after a 
preceding influenza infection (Nakamura, et al., 2011; Shahangian, et al., 2009). It was 
suggested that high amounts of IFNα/β induced by the virus inhibited the expression of the 
chemokines MCP-1, KC, and MIP-2, which led to a diminished recruitment of neutrophils and 
macrophages to the site of infection. Thus, the observed differences in the influence of type I 
IFNs on the outcome of pneumococcal infection might be owing to the differential effects of 
high or lower amounts of type I IFNs in the respective infection models. Moreover, it is 
conceivable that the infection in different body compartments also requires a different 
immune response, which would explain the diverging effects of type I IFN signaling on the 
outcome. To my knowledge, however, no study has been conducted to this day that 
investigates the role of type I IFNs, alone and together with type II IFN, in a model of primary 
pneumococcal pneumonia without any co-infections. In the following, the results of the in vivo 
experiments in this study will be discussed and compared to the findings of the previously 
mentioned studies.  
3.4.1 Influence of type I interferons on pneumococcal pneumonia in mice 
Type I IFNs have a negative effect on the control of pneumococcal replication in the lung. 
While no significant differences in the bacterial load in the lung were detectable 12 h after 
infection, single animals from the IFNAR-/- or IFNAR/IFNGR-/- strains already began clearing 
the bacteria and showed a slightly reduced bacterial load in the lung (Fig. 12A). This 
difference became more evident at 48 h p.i., when the bacterial load in both IFNAR-/- and 
IFNAR/IFNGR-/- mice was strongly and significantly reduced compared to wild-type mice 
(Fig. 12B). Moreover, the recruitment of PMNs into the lung was reduced in all knockout 
strains (Fig. 12D). IFNAR/IFNGR-/- mice showed a strongly and significantly reduced loss in 
body weight and body temperature after infection (Fig. 13B, D). These results indicate that 
type I IFNs have an overall detrimental effect for the host. Interestingly, the dissemination of 
bacteria from the lung into the blood was reduced by trend in IFNAR-/- and IFNAR/IFNGR-/- 
mice. Thus, the amount of bacteria in the lung seems to influence the dissemination into the 
blood. 
In several infection models, type I IFNs have protective effects for the host. This was 
observed in a model of pneumococcal sepsis, where mice either treated with anti-type I IFN 
antibodies (Weigent, et al., 1986) or deficient in IFNAR (Mancuso, et al., 2007) had a worse 
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outcome with an enhanced mortality and bacterial replication after systemic pneumococcal 
infection. Similar results were obtained in a meningitis model after intracranial application of 
S. pneumoniae (Mancuso, et al., 2007). The authors indicated that type I IFNs enhanced the 
production of TNFα and IFNγ in peritoneal macrophages infected with pneumococci in vitro. 
In my study, reduced levels of TNFα were detected in the BAL of infected IFNAR-/-, IFNGR-/-
, and IFNAR/IFNGR-/- mice 48 h, but not 12 h after infection (Fig. 15C). The overall levels of 
TNFα were already dropping in wild-type at this time point mice compared to the 12 h value. 
This suggests that both IFN systems are required to sustain the TNFα response throughout 
the infection. The production of IFNγ was very low 12 h p.i., and a tendency of delayed 
induction could be observed in IFNAR-/- and IFNAR/IFNGR-/- mice, which was, however, 
statistically not significant. Interestingly, both IFNAR-/- and IFNAR/IFNGR-/- mice had an 
almost abrogated IFNγ response in the BAL at 48 h after infection. Thus, in this model, 
neither TNFα nor IFNγ were significantly regulated at an early time point by type I IFNs. This 
suggests a different mechanism in this model than in the above mentioned studies. The 
reduced levels at 48 h p.i. could partly be due to the reduced bacterial loads in the lung at 
this time point. This diminished burden could require a weaker immune response by the host, 
which would be reflected in reduced cytokine levels. The discrepancy of the effect of type I 
IFNs on the outcome in the sepsis and pneumonia model can have several reasons. The 
sepsis study used a different mouse strain (129Sv/Ev) than the one used in this study 
(C57BL/6). Genetic differences in the strains could have led to a different type of immune 
response. Moreover, it is also conceivable that the immune response of a host would diverge 
in different body compartments. In the sepsis and meningitis model, an infection occurs in a 
previously sterile part of the organism, whereas the upper respiratory tract is not sterile. This 
could necessitate a differential immune response and possibly a different requirement of type 
I IFNs. Additionally, a difference in the infectious dose and the pathogenicity of the 
pneumococcal strains (serotype 2 vs. serotype 3) might also have contributed to the 
diverging outcome and regulation of cytokines. 
Another study indicated that type I IFNs were protective for the host during pneumococcal 
colonization of the nasopharynx (Parker, et al., 2011). An enhanced bacterial load was found 
7 days p.i. in the nasopharynx of IFNAR-/- mice compared to their wild-type counterparts. 
However, other studies did not argue for a role of type I IFNs during pneumococcal 
colonization since no differences in the nasopharyngeal load could be detected (Nakamura, 
et al., 2011; Shahangian, et al., 2009). These discrepancies might be either due to a different 
infection dose and/or to the use of different pneumococcal serotypes. Strains of the 
serotypes 2, 23F, and 3 were used in these studies, respectively. Serotype 2 and three are 
known to cause invasive disease (Lammers, et al., 2011; Witzenrath, et al., 2011), whereas 
serotype 23F is a non-invasive strain (Nakamura, et al., 2011). Thus, differences in infectious 
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behavior and invasiveness could explain a differential requirement of type I IFNs for the 
pneumococcal clearance. 
Regarding the influence of RANTES on the outcome in pneumococcal pneumonia, its 
protective influence does not seem to outweigh the overall negative effects of type I IFNs. A 
previous study showed that RANTES was important in restricting pneumococcal colonization 
to the nasopharynx and prevented the progression to invasion into the lung (Palaniappan, et 
al., 2006). However, despite its induction in pneumococcal pneumonia (Fig. 14), RANTES 
does not have a non-redundant effect on the recruitment of macrophages or on host 
protection. This is in agreement with a previous study, which showed that the recruitment of 
macrophages in pneumococcal pneumonia was not only dependent on RANTES, but also on 
MCP-1 and MIP-1α (Fillion, et al., 2001). Moreover, the induction of RANTES is only one part 
of a broad range of effects on the innate immune response that is regulated by IFNα/β.  
High concentrations of type I IFNs, which occur for example after an infection with influenza 
virus, were, however, detrimental to the host during a preceding or a subsequent 
pneumococcal nasopharyngeal infection (Nakamura, et al., 2011; Shahangian, et al., 2009). 
After stimulation with a type I IFN-inducing reagent or infection with influenza A virus, the 
bacterial load in the nasopharynx was significantly elevated in wild-type, but not in IFNAR-/- 
mice. This was proposed to be due to an IFNα/β-dependent inhibition of the chemokines KC, 
MIP-2, and/or MCP-1. My experiments revealed an inhibition of KC production in S. 
pneumoniae-infected macrophages by high concentrations of IFNβ as well (data not shown). 
In the model of pneumococcal pneumonia, however, these chemokines were either not or 
mostly positively regulated by the endogenously produced type I IFNs. The concentrations of 
KC or MIP-2 were similar in wild-type, IFNAR-/-, and IFNGR-/- mice at both time points 
investigated (Fig. 16C, D). The IFNAR/IFNGR double knockout mice displayed abrogated 
rather than enhanced levels of KC and MIP-2 in the BAL 48 h after infection, which could be 
owing to the reduced bacterial loads in the lung at this time point. MCP-1 levels in the BAL 
were strongly dependent on type I IFNs and to a lesser extent on type II IFN. In 
IFNAR/IFNGR-/- mice, the production of MCP-1 was significantly reduced already at 12 h 
after infection (Fig 15D). Moreover, a trend of reduced induction was also observable in 
IFNAR-/- and to a lesser extent in IFNGR-/- mice. This indicates that both type I and type II 
IFNs cooperatively stimulate the production of MCP-1 in pneumococcal pneumonia. 
However, even though it was previously suggested that reduced amounts of this chemokine 
caused an impairment in macrophage recruitment after pneumococcal infection (Nakamura, 
et al., 2011), I was not able to detect diminished amount of macrophages in the BAL of the 
mice (Fig. 12D). Additionally, the other study suggested that the inhibition of KC and MIP-2 
resulted in a defective neutrophil recruitment (Shahangian, et al., 2009). In accordance with 
the lack of KC and MIP-2 regulation in the model used in this study, a difference in early 
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PMN recruitment was not observable (Fig. 12D). At 48 h p.i., all knockout strains had 
reduced rather than increased amounts of PMNs in the BAL, which could be related to the 
diminished bacterial burden at this time point. Thus the mechanism of action in this model 
must be different from the co-infection models of influenza A virus and S. pneumoniae that 
found the chemokines MCP-1, KC, and MIP-2 to be negatively regulated by type I IFNs 
(Nakamura, et al., 2011; Shahangian, et al., 2009). It is conceivable that type I IFNs have 
different effects on chemokine production and immune cell recruitment depending on their 
concentration. Low to moderate concentrations of type I IFNs that would occur after 
pneumococcal infection appear to have no inhibitory or even stimulating (e.g. MCP-1) effects 
on these pathways, whereas higher concentrations occurring during preceding or 
simultaneous viral infections negatively regulate macrophage- and neutrophil-recruiting 
chemokines.  
The exact mechanism of the detrimental effects of type I IFNs on the host defense in 
pneumococcal pneumonia remains to be determined. They clearly have a negative influence 
on the bacterial clearance in the lung (Fig. 12). However, the expression of chemokines or 
the recruitment of PMNs or macrophages into the lung was not negatively regulated. Thus, 
an influence of type I IFNs on the apoptosis of PMNs and macrophages is not likely, since 
that would have been reflected in the cell numbers in the BAL. However, it is possible that 
type I IFNs could modulate the bactericidal functions of these cells so that they would be less 
effective in phagocytosing and killing S. pneumoniae. A previous publication demonstrated 
that type II IFN negatively influences the phagocytic uptake of unopsonized pneumococci by 
alveolar macrophages via the down-regulation of the surface expression of the scavenger 
receptor MARCO (Sun and Metzger, 2008). Given the fact that type I and type II IFNs have 
an overlapping signaling specificity, it is conceivable that IFNα/β would also have inhibiting 
effects on the phagocytosis of pneumococci. Moreover, type I IFNs could also inhibit the 
formation of ROS by macrophages. A previous study showed that IFNβ-treatment of multiple 
sclerosis patients would render their macrophages less capable of producing ROS (Lucas, et 
al., 1998). Moreover, neutrophils from patients suffering from an acute respiratory distress 
syndrome that had a high level of ISG expression showed less superoxide anion release 
(Malcolm, et al., 2011). Thus, the impact of type I IFNs induced during pneumococcal 
pneumonia on the ROS formation of neutrophils should be further investigated. 
A negative effect of type I IFNs on other neutrophil functions, such as the formation of NETs, 
has not been described so far. On the contrary, IFNα was shown to prime mature neutrophils 
for NET formation induced by the subsequent stimulation with the complement factor C5a 
(Martinelli, et al., 2004). Additionally, type I IFN signaling was necessary for the LPS-
dependent induction of iNOS in macrophages (Ohmori and Hamilton, 2001). Thus, these 
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mechanisms are not likely to be responsible for the impaired bacterial clearance due to type I 
IFN signaling. 
Another possible effect of type I IFNs on the host defense could be the impairment of IL-1β 
production by inhibiting the pro-IL-1β mRNA expression and by direct inhibition of the NLRP1 
and NLRP3 inflammasomes (Guarda, et al., 2011; Novikov, et al., 2011). The latter has been 
shown to be important for the host defense in pneumococcal pneumonia (Fang, et al., 2011; 
Hoegen, et al., 2011; McNeela, et al., 2010; Witzenrath, et al., 2011). However, in my 
experiments, I was unable to detect a clear influence of type I IFNs on the production of IL-1β 
(Fig. 16A). The concentrations were reduced rather than enhanced at later time points in the 
knockout mice, which was most likely due to the reduced bacterial load in the lung of these 
mice. Another inhibitory mechanism of type I IFNs is the induction of IL-10, which has many 
anti-inflammatory effects (Cyktor and Turner, 2011; Guarda, et al., 2011). IL-10 was shown 
to inhibit the secretion of inflammatory cytokines, including IFNγ, TNF, IL-1, and GM-CSF 
(Cyktor and Turner, 2011). However, the concentrations of these cytokines in the lung during 
pneumococcal pneumonia were not negatively regulated by type I IFNs (Fig. 15, 16). Thus, a 
prominent anti-inflammatory effect of type I IFNs via the enhanced production of IL-10 does 
not seem to contribute to the observed phenotype. 
The molecular mechanisms of the detrimental effects of type I IFNs on the host remain to be 
identified. Future research could focus on the effects of IFNα/β on macrophage and 
neutrophil function. It is also possible, that type I IFNs negatively regulate other innate 
immune defense mechanisms, such as the production of antimicrobial peptides. 
3.4.2 Type II interferon in pneumococcal pneumonia 
The effect of type II IFN in S. pneumoniae pneumonia is less pronounced than the effect of 
type I IFNs. IFNGR-/- mice had a slightly reduced bacterial load in the lungs compared to 
wild-type littermates (Fig. 12B). However, this difference was less than the reduction 
observed in comparison to IFNAR-/- mice and did not reach statistical significance. The small 
reduction in bacterial numbers in the lung of IFNGR-/- mice is in agreement with a previously 
published study (Rijneveld, et al., 2002). In contrast, other studies suggested a protective 
effect of IFNγ in pneumococcal pneumonia using pneumococcal strains of different serotypes 
(Rubins and Pomeroy, 1997; Yamada, et al., 2011) or anti-IFNγ antibody treatment instead 
of knockout mice (Yamamoto, et al., 2004). However, the studies that reported a protective 
effect of IFNγ for the host defense against pneumococcal pneumonia used serotype 2 or 
serotype 19 strains (Rubins and Pomeroy, 1997; Yamada, et al., 2011), while in this study 
and the one of Rijneveld et al, a serotype 3 strain was used. As previously mentioned, S. 
pneumoniae serotypes differ in the course of infection, which might explain differential 
requirements for IFNγ in the host-response to these bacteria. Moreover, the infectious dose 
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could also be important for a protective effect of type II IFN. Studies only reported a 
protective effect of IFNγ after sublethal doses of infections in wild-type mice, while a certain 
percentage of the IFNγ-deficient mice would succumb to infection (Rubins and Pomeroy, 
1997; Yamamoto, et al., 2004). In accordance, one study could only find a protective effect of 
type II IFN after low-dose infection with pneumococci and not after infection with higher 
doses (Yamada, et al., 2011). In both this study and the one from Rijneveld et al, a high 
infectious dose was used that would kill all or the majority of the wild-type mice. Thus, a 
protective effect of type II IFN on the survival of mice in pneumococcal pneumonia seems to 
be detectable only after low-dose infection with S. pneumoniae. 
Compared to IFNAR-/- mice, the bacterial clearance in IFNGR-/- mice was not as efficient 
and a higher bacterial burden in the BAL could be detected in the lung. However, the 
clearance of pneumococci in the lung was still improved compared to wild-type mice. This 
could be explained by the fact that type I and type II IFNs are able to induce an overlapping 
set of genes. Thus, IFNγ might also induce some genes similarly to IFNα/β that are 
detrimental to the host response against S. pneumoniae. This would explain the similar 
phenotype in both mouse strains. Type I IFNs seem, however, to induce these genes 
stronger than type II IFN, which might thus result in a stronger clearance in IFNAR-/- mice 
compared to IFNGR-/- mice. 
3.4.3 Synergistic effects of type I IFNs and type II IFN 
Notably, type I IFNs seem to be necessary for a sustained type II IFN production since IFNγ 
was almost absent in the BAL of IFNAR-/- and IFNAR/IFNGR-/- mice (Fig. 15B). This is in 
agreement with other studies that suggest a contribution of type I IFNs to type II IFN 
production (Carrero, et al., 2006; Freudenberg, et al., 2002). The reduced bacterial load in 
the knockout mice might partly have influenced a weaker expression of IFNγ in the BAL. 
However, even though a reduction of the bacterial load by trend is observable in IFNGR-/- 
mice, the production of type II IFN in these mice seems even slightly enhanced. Taken 
together, this suggests a contribution of type I IFNs on the secretion of IFNγ also in this 
infection model. This leads to a model, where type I IFNs mediate the sustained production 
of type II IFN and both IFN families synergistically weaken the immune response against S. 
pneumoniae. In agreement with this model, IFNAR/IFNGR double knockout mice show by 
trend the highest reduction in bacterial numbers (Fig. 12B). Moreover, a significant reduction 
in the loss of body weight and body temperature was only prominent in the double knockout 
mice (Fig. 13B, D). The single knockout strains showed an unaltered loss in body weight and 
only a significantly reduced loss in body temperature at the later time points. This further 
indicates a synergistic effect of both type I and type II IFNs on the susceptibility of the host. 
However, a significant synergistic mechanism on the early cytokine and chemokine 
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production could only be demonstrated in the case of MCP-1 (Fig. 15). The strongly reduced 
chemokine concentrations in the double knockout mice at 48 h p.i. are likely a result of the 
reduced bacterial burden and a reduced immune response. Thus, they do not directly 
indicate a synergistic effect of type I and type II IFNs on the induction of pro-inflammatory 
mediators in pneumococcal pneumonia in vivo.  
Further research is required to clarify how type I IFNs inhibit the clearance of pneumococci in 
the lung. Since neither the investigated chemokines nor the cell recruitment into the lung are 
able to explain the observed phenotype, it is necessary to investigate the influence of type I 
and type II IFNs on other innate immune mechanisms, such as the antibacterial functions of 
phagocytes, the production of antimicrobial peptides, etc. (as discussed above). 
3.5 Conclusion and further outlook 
This study shows that different serotypes of S. pneumoniae induce a type I IFN response in 
vitro depending on the virulence factor PLY. The results lead to the model that pneumococci 
are phagocytosed and digested in the endosome (Fig. 17). After forming pores and 
compromising the endosomal membrane integrity, a pneumococcal PAMP, which is most 
likely pneumococcal DNA, is able to access the cytosol. There it is sensed by one or several 
PRRs, which activate the adaptor proteins STING as well as the transcription factor IRF3. 
This leads to the transcription, translation, and secretion of type I IFNs. Moreover, MyD88 is 
activated, which further promotes the induction of IFNα/β. After secretion and binding to the 
type I IFN receptor, type I IFNs modulate the expression of ISGs in the infected 
macrophages and non-infected neighboring cells in vitro. In vivo, type I IFNs were shown to 
negatively affect the immune response of the host in pneumococcal pneumonia. IFNAR-/- 
and IFNAR/IFNGR-/- mice had a significantly reduced bacterial burden in the lung. Moreover, 
IFNAR/IFNGR-/- mice had a significantly diminished loss of body weight and body 
temperature after infection. The detrimental effect of type I IFNs on pneumococcal clearance 
seems to be independent of the recruitment of neutrophils and macrophages. Moreover, a 
strong modulation of pro-inflammatory cytokine expression by IFNα/β could not be 
demonstrated. Future experiments should further elucidate the signaling pathways leading to 
the type I IFN induction by S. pneumoniae. Moreover, the cellular effects of type I IFNs that 
lead to an impaired host response in pneumococcal pneumonia should be identified. 
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Fig. 18: Innate immune pathways triggered by S. pneumoniae. Pneumococcal cell wall components and 
PLY are sensed by TLRs on the plasma membrane or in the endosomal compartment. Moreover, 
peptidoglycan and pneumococcal DNA can access the cytosol and are sensed by NOD2 and AIM2, 
respectively. NLRP3 is activated depending on PLY. Stimulation of TLRs and NOD2 leads to the activation 
of NF-κB and the transcription of pro-inflammatory genes, including pro-IL-1β, TNFα, and KC. The 
activation of inflammasomes leads to the activation of caspase-1 and the subsequent proteolytic 
cleavage of pro-IL-1β into its mature form. The mature IL-1β is then released. In addition to the described 
pathways, pneumococcal DNA appears to be sensed by an unknown DNA receptor that leads to the 
activation of IRF-3 and the production of type I IFNs via the adaptor molecules STING and MyD88. 
This study expands the knowledge of the innate immune pathways that are triggered after 
infection with S. pneumoniae. An extended model of all the cellular pathways that were 
involved in the sensing of pneumococci is shown in Fig. 18. Pneumococcal cell wall 
components are detected by TLRs in the plasma membrane and by NOD2 in the cytosol. 
Moreover, NOD2 has been indicated to be involved in the induction of type I IFNs in vivo. 
Pneumococcal DNA is sensed in the endosome by TLR9, but is also able to escape into the 
cytosol where it stimulates further immune pathways. I was able to show that the cytosolic 
DNA sensor AIM2 is activated during infection with S. pneumoniae. AIM2 forms an 
inflammasome and thus contributes to the post-translational processing and secretion of IL-
1β. Moreover, sensing of a pneumococcal PAMP in the cytosol, which is likely to be DNA 
activates the production of type I IFNs via a STING and IRF3-dependent pathway. 
Additionally, MyD88 also contributes to the induction of type I IFNs. In vivo, type I IFNs have 
a negative effect on the replication of S. pneumoniae in the lung of mice despite the positive 
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effects on the production of type II IFN and on the induction of chemokines, such as 
RANTES and MCP-1.  
Regarding the cell signaling pathways involved in the induction of type I IFNs, I demonstrated 
an involvement of the adaptor molecules STING and MyD88 and of the transcription factor 
IRF3. However, the PRR that senses pneumococci in the cytosol remains elusive. RNAi 
experiments against DAI and IFI16 did not reveal a non-redundant participation of these 
receptors in the induction of IFNβ after infection with S. pneumoniae. The helicases DDX41 
and DHX36 are also possible candidates for being the receptors that sense pneumococcal 
DNA in the cytosol. Improved RNAi techniques such as shRNAs or cells of yet-to-be-
generated knockout mice should be used to clarify their involvement in the type I IFN 
response after infection with S. pneumoniae. Since STING is not only an adaptor molecule 
for DNA-sensing receptor pathways, but also involved in the sensing of cyclic di-nucleotides 
as well, it is conceivable that this might be a pneumococcal PAMP also contributing to the 
type I IFN response. Thus, future experiments could focus on this question by utilizing a 
STING-mutant that would be defective in sensing cyclic di-GMP, but not in relaying signal 
from the upstream DNA-sensing PRR (as described in (Burdette, et al., 2011)). Moreover, 
inhibition of the enzyme di-adenylate cyclase, which is responsible for the production of 
cyclic di-AMP in S. pneumoniae, could clarify the contribution of this cyclic di-nucleotide in 
activating the innate immune response during infection. However, the involvement of both 
MyD88 and STING suggests that more than one pathway is involved in the type I IFN 
response so that several cytosolic signaling components are possibly involved in sensing 
components of S. pneumoniae during infection.  
Employing an in vivo model of pneumococcal pneumonia, I was able to show that the net 
effect of type I IFNs on the bacterial replication was not protective, but detrimental to the 
host. Future studies should further investigate these findings and determine the influence of 
type I and type II IFNs on other parts of the innate immune system. These could focus on 
barrier functions of the lung endothelial/epithelial barrier and on the expression of anti-
microbial peptides and complement factors. Since it was shown that IFNγ inhibits the 
phagocytosis in alveolar macrophages via down regulation of the surface expression of the 
scavenger receptor MARCO, future research could focus on the influence of type I IFNs on 
the phagocytosis of S. pneumoniae by neutrophils or macrophages. Since type I IFNs and 
type II IFN induce an overlapping set of gene in cells, a role of IFNα/β in the regulation of 
phagocytosis seems possible. Moreover, future studies should also focus on a possible 
influence of type I IFNs on the production of reactive oxygen species, since previous studies 
indicated an inhibited production of these antimicrobial molecules after IFNβ-treatment of 
macrophages in patients. 
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The investigation of the type I IFN response in S. pneumoniae pneumonia will complement 
the knowledge about the innate immune response that is activated during pneumococcal 
infection. The identification of the molecular mechanisms that are activated by IFNα/β and 
impair the host defense against S. pneumoniae will hopefully contribute to the development 
of new therapeutic strategies in the future. 
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4. Materials and Methods 
4.1 Bacteria 
In vitro, cells were infected with the Streptococcus pneumoniae serotype 2 strain D39 or the 
serotype 4 strain TIGR4. Isogenic mutants of D39 included pneumococci deficient of the 
capsule (D39Δcps), of pneumolysin (D39Δply), or double deficient of both virulence factors 
(D39Δcps/Δply). For the TIGR4 strain, isogenic mutants deficient of the capsule 
(TIGR4Δcps) or double deficient of the capsule and PLY (TIGR4 Δcps/Δply) were used. In 
vivo, the serotype 3 strain NCTC7978 was used. All strains were kindly provided by Prof. S. 
Hammerschmidt. 
4.1.1 Culture of S. pneumoniae 
The bacteria were stored at -80°C in THY broth (30g/l Todd-Hewitt Broth, 5g/l yeast extract) 
containing 10% glycerol. Before use, pneumococci were cultured on Columbia blood agar + 
5% sheep blood for 12 h. Mutant strains additionally required antibiotics on the agar plate (40 
µl per plate): D39Δcps = 50 mg/ml kanamycin; D39Δply = 1 mg/ml erythromycin; D39 
Δcps/Δply = 50 mg/ml kanamycin + 1 mg/ml erythromycin; TIGR4Δcps and Δcps/Δply = 5 
µg/ml erythromycin. 12 h after spreading of the bacteria on the agar plate, single colonies 
were transferred into THY media to yield OD600 = 0.03 – 0.06. OD600 = 1 equates to 10
9 
cfu/ml. Liquid cultures were incubated at 37°C + 5% CO2 for 3-4 h until the bacteria reached 
a phase of logarithmic growth (OD600 = 0.2 – 0.4). Bacteria were pelleted at 2,700 g for 10 
min. The pellet was resuspended in RPMI1640 blank media and the appropriate dilutions 
were prepared and added to the cells. For analysis of IFNβ mRNA induction, the cells were 
infected for 6 h. For measurement of protein levels in the supernatant, the infection time was 
16 h. 
4.1.2 Preparation of bacterial extracts 
Pneumococcal extracts were prepared as described elsewhere (Charrel-Dennis, et al., 
2008). Briefly, S. pneumoniae D39 wild-type or ΔPLY were grown until OD600 = 0.8. 
Subsequently, the bacteria were centrifuged at 2900 g for 10 min and the pellet was stored in 
liquid nitrogen. Afterwards, the pellet was thawed on ice and treated with lysozyme (1 mg/ml) 
at 37°C for 10 min. Next, the sample was subjected to ultrasound (2 min, 50% pulse chase) 
while keeping it on ice. Then, the debris was pelleted (20,000 g, 10 min, 4°C) and the ion 
concentrations in the supernatant were adjusted to 2 mM MgCl2, 50 mM KCl, and 20 mM 
Tris-HCl. Subsequently, the extracts were divided into 60 µl aliquots and digested with 
nucleases or proteinase. Nucleases (6.25 U per 60 µl) were added to the respective tubes 
(DNase; RNase A; RNase H) and incubated at 37°C and 300 rpm for 45 min. When 
proteinase K (0.216 U) was added, the reaction mixture was incubated at 54°C and 500 rpm 
for 45 min. 1.5 µl of a 40x EDTA solution were added to yield a final concentration of 2.5 mM 
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and the aliquots were incubated at 70°C for 10 min. The debris was pelleted at 16,000 g for 5 
min. The supernatants were collected and stored at -20°C. For transfections, 0.25 µl extract 
was used per well. 
 
4.2 Mice 
Wild-type mice as well as IFNAR-/- (Muller, et al., 1994), IFNGR-/- (Huang, et al., 1993), and 
IFNAR/IFNGR-/- mice were on a C57BL/6 background. All animal experiments were approved 
by the local ethics committee (application number G 0342/10). 
 
4.3 Cell culture 
4.3.1 Culture of human cells 
The human alveolar epithelial cell line A549 (DSMZ) was cultured in DMEM medium 
containing 10% FCS and 4.5 mM L-glutamine.  
Human peripheral blood mononuclear cells (PBMCs) were isolated with a Pancoll gradient 
from buffy coats. Buffy coats were diluted 1:1 with EDTA buffer (RPMI 1640 + 5% FCS + 
0.2mM EDTA). 20 ml Pancoll solution was overlaid with 25 ml diluted buffy coat and 
centrifuged for 25 min at 800 g. Cells at the phase separation were isolated and washed 
twice with EDTA buffer. Cells in 10 ml EDTA buffer were then overlaid over a diluted Pancoll 
solution (10 ml Pancoll + 1.4 ml PBS) and centrifuged as above. The cells at the phase 
separation were isolated, washed twice with EDTA buffer, and seeded into 24 wells in PBS 
at a concentration of 3x106 cells/ml. Cells adhered over 2 h at 37°C + 5% CO2 and were 
subsequently transferred into RPMI 1640 + 10% FCS + 4.5 mM L-glutamine. At day 3 and 
day 6, half of the media was replaced and fresh media was added. The adhered cells were 
washed twice at day 7 and then used for experiments. 
Human alveolar macrophages were obtained from the BAL of human patients. The BAL was 
centrifuged at 280 g for 10 min. The pellet was resuspended in PBS + 100 µg/ml 
Penicillin/Streptomycin (Pen/Strep). Cells were seeded at a concentration of 4x105 cells/ml 
and adhered for 2 h at 37°C + 5% CO2. Afterwards, cells were cultured overnight in RPMI 
1640 + 10% FCS + 4.5 mM L-glutamine + 100 µg/ml Pen/Strep. The next day, cells were 
washed twice with PBS, transferred into antibiotic-free medium, and used for the 
experiments.  
Studies with human alveolar macrophages as well as PBMCs were approved by the local 
ethics committee. 
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4.3.2 Culture of murine cells 
L929 fibroblasts were utilized to produce macrophage colony-stimulating factor (M-CSF)-
enhanced medium. Cells were cultured in RPMI 1640 + 10% FCS + 4.5 mM L-glutamine and 
seeded into T175 flasks. After reaching confluency, the cells were stored in the incubator for 
ten days. After this time, the medium was removed and sterile-filtered (0.2 µm). After division 
into aliquots of 50 ml, the supernatants were stored at -80°C until further use. 
BMMs were isolated from femurs and tibiae of C57BL/6 wild-type or C57BL/6 knockout mice 
(see 4.3.3). BMMs from IRF3-/- (Sato, et al., 2000) were kindly provided by C. Roy (Yale 
University, USA). NOD2-/- BMMs (Kobayashi, et al., 2005) were kindly provided by A. Dorhoi 
(MPI-IB, Berlin) with permission of R. Flavell (Yale University, USA). Bones from Cardif-/- 
(MAVS-/-) mice (Michallet, et al., 2008) were supplied by J. Tschopp (University of 
Lausanne) and bones from TLR2/3/4/7/9-/- mice (Conrad, et al., 2009) were a gift from C. 
Kirschning (University of Duisburg-Essen). Bones from MyD88-/- mice (Heimesaat, et al., 
2010) were kindly provided from M. Heimesaat / S. Bereswil (Charité Berlin) and bones from 
IFNAR-/- mice (Stetson and Medzhitov, 2006) were supplied by U. Klemm (MPI-IB) . 
4.3.3 Isolation and culture of murine bone marrow-derived macrophages 
Femurs and tibiae of wild-type or the respective knockout mice were isolated from sacrificed 
mice. The bones were washed once in 70% ethanol and then once in RPMI1640. The bones 
were transferred into 20 ml RPMI and crushed in a sterilized mortar. The suspension was 
passed through a cell strainer (70 µm) and the cells were centrifuged at 150 g for 10 min. 
The pellet was resuspended in FCS + 10% DMSO. Cells were frozen to -80°C in aliquots of 
107 cells/ml and then stored in liquid nitrogen. 
For culturing BMMs, bone-marrow aliquots were thawed and transferred into “BMM growth 
medium” (RPMI 1640 + 20% FCS + 30% L929 fibroblast supernatant (see 4.3.2) + 4.5 mM L-
glutamine + 100 µg/ml Pen/Strep). Cells were centrifuged (230 g, 10 min), resuspended in 20 
ml BMM growth medium and divided into two Optilux petri dishes. After 4 days, 10 ml growth 
medium per dish was added. Cells grew to confluency after 7-10 days. To seed the BMMs, 
cells were scraped in PBS + 2 mM EDTA, washed, and resuspended in “BMM replating 
medium” (RPMI 1640 + 10% FCS + 15% L929 fibroblast supernatant + 4.5 mM L-glutamine). 
Cells were seeded at a concentration of 4x105 cells/ml. After overnight incubation, the 
medium was replaced by fresh BMM replating medium. Subsequently, the cells were used 
for the experiments. 
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4.3.4 Cell isolation and co-culture of murine alveolar macrophages with alveolar 
epithelial cells 
Murine alveolar epithelial cells and alveolar macrophages were isolated from mouse lungs as 
described elsewhere (Cakarova, et al., 2009). In brief, mice were anesthetized with 
Ketamine/Xylazine and then sacrificed by final blood withdrawal from the vena cava under 
narcosis. A blunt needle was inserted into the trachea. The lung was perfused with HBSS 
through the right heart chamber to remove all blood. Afterwards the lung was digested from 
the inside and outside with 5000 U Dispase for 40 min. This was followed by 10 min of 
DNase digestion (0.1 mg/ml in DMEM + 2.5% HEPES + 10% FCS + 4.5 mM L-glutamine + 
100 µg/ml Pen/Strep) and dissociation of the lung into a cell suspension. The suspension 
was passed through cell strainers (100 µm, 40 µm, 20 µm) and centrifuged twice at 100 g, 8 
min, 4°C to pellet the desired cells. The pellet was resuspended and incubated with 
biotinylated antibodies (anti-CD45: 0.45 µg/1x106 cells, anti-CD31: 0.2 µg/1x106 cells, anti-
CD16/32: 0.34 µg/1x106 cells) for 30 min at 37°C + 5% CO2. The cells were washed twice in 
DMEM/HEPES medium without FCS and incubated with magnetic Dynabeads Biotin Binder 
(4.3x106 beads/106 cells) for 30 min with gentle shaking. The antibody-bound cells were 
separated from the alveolar epithelial cells by incubation on a magnet for 15 min. The 
alveolar epithelial cells were washed in DMEM + 2.5% HEPES + 10% FCS + 4.5 mM L-
glutamine + 100 µg/ml Pen/Strep. Then they were counted and seeded on upside-down cell 
culture inserts at a density of 3x105 cells per insert. An aliquot was taken for FACS analysis 
to determine the purity of the isolated cells measuring expression of the alveolar epithelial 
cell marker pro-SP-C and the absence of the leukocyte marker CD45 and endothelial cell 
marker CD31 on the cell surface. Purity was always around 95%. Cells adhered for 2 h in the 
incubator. The inserts were then flipped into their normal position and the cells were 
incubated in DMEM/HEPES media for 5 days. Medium was changed once at day 3. 
Alveolar epithelial cells were obtained from mice that were sacrificed as mentioned above. 
The trachea was exposed and a blunt needle was inserted. The lung was washed 10x with 
500 µl PBS + 2 mM EDTA. The lavage fluid from all mice was combined and stored at 4°C. 
The alveolar macrophages were centrifuged at 300 g for 10 min and the pellet was 
resuspended in RPMI 1640 + 10% FCS + 4.5 mM L-glutamine + 100 µg/ml Pen/Strep. Cells 
were seeded at a density of 4x105 cells per 24 well and adhered for 2 h at 37°C + 5% CO2. 
Subsequently, the cells were transferred into new medium and incubated overnight. 
The next day, alveolar macrophages were washed in PBS and transferred in DMEM/HEPES 
+ 2% FCS + 4.5 mM L-glutamine. Alveolar epithelial cells were washed in PBS and the cell 
culture inserts were transferred to alveolar macrophages to establish the co-culture. Cells 
were infected with S. pneumoniae D39 wild-type for 6 h (mono-culture) or 16 h (co-culture) 
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with MOI 2.5 (mono-culture, 6 h) or 0.025 (co-culture, 16 h). Subsequently, supernatants 
were stored for ELISA and cells were lysed for RNA analysis. 
 
4.4 Molecular biology 
4.4.1 RNA interference 
Murine bone-marrow-derived macrophages were transfected with small interfering RNA 
(siRNA) using the HiPerFect reagent. BMMs were seeded at a density of 1x105 cells per 48 
well (c = 4x105 cells/ml) and were incubated at 37°C + 5% CO2 until they adhered. 48 h prior 
to infection, 1x105 cells were transfected with 30 pmol siRNA and 1.5 µl HiPerFect per well. 
The siRNA was diluted in RPMI1640 medium without any additives and shortly vortexed. 
Afterwards, the HiPerFect reagent was added. The solution was vortexed for 10 seconds and 
then incubated at room temperature for 5-10 minutes. Afterwards, 50 µl of the transfection 
mix were added per well. After gentle shaking, the cells were incubated for 48 h at 37°C + 
5% CO2. Before further stimulation or infection, the cells were washed once to remove the 
transfection reagent. Stimulations or infections were done in “BMM replating medium” (see 
4.3.2). The siRNA-mediated reduction of mRNA expression was assessed with quantitative 
RT-PCR using mRNA-specific primers and probes. RNA interference for STING was 
performed using a pool of the siRNA sequences STING-1 and STING-2. 
Tab. 2: siRNA sequences 
Target gene Sense Antisense 
control UUCUCCGAACGUGUCACGUtt ACGUGACACGUUCGGAGGAGAAtt 
AIM2-1 GAAAGAAGCUGAACGUAAAtt UUUACGUUCAGCUUCUUUCtt 
AIM2-2 GCACAGUUUAAAGAUAAAUtt AUUUAUCUUUAAACUGUGCgt 
STING-1 GGAUCCGAAUGUUCAAUCAtt UGAUUGAACAUUCGGAUCCgg 
STING-2 GGUCCUCUAUAAGUCCCUAtt UAGGGACUUAUAGAGGACCag 
DAI-1 GGAGCUCAGUACAUCUACAtt UGUAGAUGUACUGAGCUCCgt 
DAI-2 GAGCUUCAUUCAACAUGCAtt UGCAUGUUGAAUGAAGCUCct 
IFI16-1 CCGAAAGAACACAAUCUAUtt AUAGAUUGUGUUCUUUCGGtt 
IFI16-2 CAACAAAUGGUUAUCUCAAAtt UUUGAGAUAACCAUUGUUGga 
IFI16-3 GUUUCAUCAAGAUAUCAAAtt UUUGAUAUCUUGAUGAAACtg 
4.4.2 DNA purification 
DNA from S. pneumoniae was purified with the DNeasy Blood & Tissue Kit according to 
protocol. In brief, D39 wild-type pneumococci were cultured on blood agar plates overnight 
and inoculated in THY media the next morning (see above). The culture was incubated at 
37°C + 5% CO2 until OD600 = 0.8. Pneumococci were centrifuged at 2900 g for 10 min. The 
supernatant was discarded and the pellet was resuspended in 200 µl PBS. After freezing of 
 
 
78 
this bacterial suspension in liquid nitrogen, it was stored at -20°C overnight. The next day, 
the bacteria were thawed and 4 µl RNase A (100 mg/ml) were added. After gentle vortexing, 
the suspension was incubated at room temperature for 2 min. 20 µl proteinase K (600 
mAU/ml) and 200 µl ATL buffer were added and the bacteria were incubated at 70°C for 10 
min followed by 95°C for 3 min. The debris was pelleted (16,000 g, 10 min), the supernatant 
was transferred into a new tube, and 200 µl ethanol (100%) were added to the supernatant. 
The solution was transferred onto a DNeasy Mini Spin column and centrifuged for 1 min at 
6,000 g. After adding the column into a new collection tube, 500 µl AW1 buffer was added 
and the column was centrifuged again for 1 min at 6,000 g. Next, the column was transferred 
into another collection tube and 500 µl AW2 buffer were added. The column was centrifuged 
for 3 min at 16,000 g and afterwards transferred into an elution tube. 200 µl pre-warmed 
(70°C) AE elution buffer were added to the column, incubated at room temperature for 1 min 
and then centrifuged at 6,000 g for 1 min. The concentration was determined by measuring 
the OD260 in a quartz cuvette. Moreover, the integrity of the isolated DNA was determined in 
a 1% agarose gel. 
4.4.3 RNA purification and transcription to cDNA 
RNA was extracted from cells using the “PerfectPureTM RNA Cultured Cell Kit” (5Prime) or 
the “Nucleospin® II Kit” (Macherey & Nagel) according to the manufacturer’s instructions 
including digestion of genomic DNA.  
For isolation of RNA with the “PerfectPureTM RNA Cultured Cell Kit”, the supernatant from 
stimulated/infected cells was removed and 200 µl lysis buffer was added to the cells. The 
lysed cells were stored at -20°C until further purification. Then, the lysate was pipetted 10 
times up and down using a filtered pipette tip and loaded onto a purification column. After 
centrifugation at 16,000 g for 1 min at room temperature, 400 µl “Wash 1” solution was 
added per column. After another centrifugation step (16,000 g, 1 min) the columns were 
transferred into new collection tubes. The lyophilized DNase was reconstituted in 2.6 ml 
DNase buffer and stored on ice. 50 µl DNase solution was added per tube and incubated for 
15 min at room temperature. Then, 200 µl “DNase wash solution” was added per tube and 
centrifuged at 16,000 g for 1 min. Another 200 µl DNase wash solution was added and 
centrifuged at 16,000g for 2 min. After transferring the purification column into a new 
collection tube, the column was washed twice with 200 µl “Wash 2 buffer” and centrifuged at 
16,000 g for 1 min after the first wash and then for 2 min after the second wash. Next, the 
column was transferred into a new collection tube and 50 µl “Elution solution” was added per 
tube. The columns were incubated for 1 min at room temperature and then centrifuged at 
16,000 g for 1 min. 10 µl RNA was used for transcription to cDNA. The remaining RNA was 
stored at -80°C. 
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For isolation of RNA with the “Nucleospin® II Kit”, the supernatant of the stimulated/infected 
cells was removed and 350 µl RA1 buffer (containing 1% β-mercapto ethanol) was added per 
well. The lysate could be stored at -20°C and then used for further purification. The lysate 
was applied onto a “NucleoSpin® Filter column” and centrifuged for 1 min at 11,000 g. 350 µl 
ethanol (70%) was added per lysate, gently mixed, and then applied onto a “NucleoSpin® 
RNA II column”. The columns were centrifuged for 30 sec at 11,000 g and then transferred 
into a new collection tube. 350 µl “MDB buffer” was added per tube and centrifuged for 1 min 
at 11,000 g. After transferring the column into a new collection tube, the DNA on the column 
was digested. Lyophilized DNase was reconstituted with 540 µl RNase-free H2O and stored 
on ice. Per column, 10 µl reconstituted DNase was added to 90 µl DNase reaction buffer. 95 
µl of the DNase solution was then applied on each column and incubated for 15 min at room 
temperature. Next, 200 µl “RA2 buffer” was added per column and centrifuged at 11,000 g 
for 30 sec. 600 µl “RA3 buffer” was then added to the column and centrifuged again at the 
same speed and time. After transferring the RNA-binding column into a new collection tube, 
another 250 µl “RA3 buffer” was added per column and centrifuged at 11,000 g for 2 min. 
The “NucleoSpin® RNA II column” was then transferred into a collection tube. 40 µl RNase-
free ddH2O was added per column, incubated at room temperature for 1 min, and then 
centrifuged at 11,000 g for 1 min. 10 µl RNA were used for transcription to cDNA. The rest of 
the RNA was stored at -80°C. 
RNA was transcribed to cDNA using the “High Capacity Reverse Transcription Kit” (Applied 
Biosystems). 10 µl RNA was pipetted into a 0.5 ml Eppendorf tube (RNase-free) and stored 
on ice. A mastermix was prepared containing 4.2 µl ddH2O, 2 µl Reverse Transcription 
buffer, 2 ml Random Primers, 0.8 µl dNTPs, and 1 µl Reverse Transcriptase per reaction. 10 
µl mastermix were added per tube yielding a final volume of 20 µl. The reaction mixture was 
shortly vortexed and centrifuged. The tubes were incubated in a thermo cycler for 10 min at 
25°C, then for 2 h at 37°C, and lastly for 5 sec at 85°C. After this incubation, the samples 
were diluted with 75 µl ddH2O per tube and stored at -20°C. 
4.4.4 Quantitative RT-PCR 
Relative mRNA expression was measured using quantitative RT-PCR. cDNA samples (see 
above) were thawed and stored on ice. A reaction mixture was prepared containing 10 µl 
“Gene Expression Master Mix” (2x concentrated), 1 µl Taqman Assay (20x concentrated, 
self-designed or purchased from Applied Biosystems), and 4 µl ddH2O. 15 µl of the reaction 
mixture and 5 µl of a diluted cDNA sample (see above) were added per 96 well. Expression 
of GAPDH was used as an internal reference for normalization of the data. The 
oligonucleotide concentrations in the Taqman Assay were 18 nmol/ml for the forward- and 
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reverse-primer and 5 nmol/ml for the probe. The annealing temperature for all assays was at 
60°C. 
Tab. 3: sequences for quantitative RT-PCR primers 
Target 
gene 
Forward Reverse Probe (5’-Fam, 3’-TAMRA) 
hGAPDH TGACAACAGCCTCAAG
ATCATCA 
ACTGTGGTCATGAGTC
CTTCCA 
TCCTGCACCACCAACTGCTTAG
CACC 
hIFNβ CCAACAAGTGTCTCCT
CCAAATT 
GTAGGAATCCAAGCAA
GTTGTAGCT 
TGTTGTGCTTCTCCACTACAGC
TCTTTCCA 
mGAPDH TGTGTCCGTCGTGGAT
CTGA 
CCTGCTTCACCACCTTC
TTGA 
CCGCCTGGAGAAACCTGCCAA
GTATG 
mIFNβ AGAAAGGACGAACATT
CGGAAA 
TCCGTCATCTCCATAG
GGATCTT 
ATGGAAAGATCAACCTCACCTA
CAGGGCG 
mRANTES GGAGTATTTCTACACC
AGCAGCAA 
CACACACTTGGCGGTT
CCT 
CCAATCTTGCAGTCGTGTTTGT
CACTCG 
mIRF7 GCATGGCAGGTGGAAG
CT 
ACATGATGGTCACATC
CAGGAA 
AGCTCTCACCGAGCGCAGCCT
TG 
    
 Assay-ID (Applied Biosystems) 
mAIM2 Mm01295719_m1 
mSTING Mm01158119_g1 
mDAI Mm00457979_m1 
mIFI16 Mm00492602_m1 
mISG15 Mm01705338_s1 
 
4.4.5 ELISA 
Concentrations of mIFNβ, mIL-1β, and mRANTES in cell-free supernatants were quantified 
by commercially available sandwich ELISA Kits (PBL Biomedical Laboratories; eBioscience; 
RayBiotech Inc.). Undiluted cell culture supernatants (100 µl per well) were used in all ELISA 
assays. 
Cytokines in broncho-alveolar lavage fluids from mice were quantified by a sandwich ELISA 
(mRANTES) or by a cytokine multiplex assay (Bioplex; Bio-Rad, Hercules, CA). For the 
RANTES ELISA, samples were either undiluted (12 h p.i.) or diluted 1:2 in Assay Diluent A 
(48 h p.i.). The Bioplex Assay was performed according to protocol with 50 µl undiluted BAL 
sample per well. Reagents for the mouse cytokine group 1 and group 2 were mixed together 
before the assay as indicated in the instruction manual. Cytokines from group 3 had to be 
measured separately. 
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4.5 Cell biology 
4.5.1 Inhibitors/Stimulations 
BMMs were treated with Cytochalasin D (2 µM), Bafilomycin A1 (200 nM), Chloroquine (50 
µM), or ammonium chloride (5 mM) for 30 min prior to infection and during infection. Where 
indicated, BMMs were treated with 100 ng/ml LPS, 100 ng/ml MALP2, 10 µg/ml MDP, or 500 
U/ml mIFNβ for 6 h or 16 h. 
4.5.2 Transfections 
Cells were transfected with 0.25 µg poly dA:dT, poly I:C, pppRNA, pneumococcal DNA, or 
0.25 µl pneumococcal extract per well using 0.25 µl Lipofectamine2000 according to the 
manufacturer’s instructions.  
In brief, the indicated nucleic acids or extracts were diluted to a volume of 25 µl with 
RPMI1640. 0.25 µl Lipofectamine2000 was diluted separately in RPMI1640 to a volume of 25 
µl as well. Both solutions were vortexed and incubated at room temperature for 2-5 min. 
Then, the solutions were mixed together, vortexed again, and incubated at room temperature 
for 20 min. The BMMs (1x105 cells per 48 well) were washed once and 150 µl RPMI1640 
was added per well. 50 µl Lipofectamine2000 transfection mix was added per well. The cells 
were incubated for 6 h and then lysed in RNA lysis buffer according to protocol (see above). 
pppRNA was kindly provided by S. Bauer (University of Marburg). 
4.5.3 Infection with Streptococcus pneumoniae 
Cells were infected with S. pneumoniae at different MOIs. The pneumococci were grown as 
described above, transferred into RPMI 1640, and adjusted to the appropriate dilutions. 
Bacteria in RPMI were added to the cells and then incubated for 1 h (phagocytosis assay, 
MOI 2.5), 6 h (RNA induction, MOI 0.025 or 2.5), or 16 h (ELISA and Co-Culture, MOI 0.0025 
or 0.025) at 37°C + 5% CO2. After this incubation time, the supernatants were either 
collected and stored at -20°C or discarded. The cells were lysed in RNA lysis buffer 
according to protocol. 
4.5.4 Bacterial phagocytosis assay 
To determine the phagocytosis of pneumococci by BMMs, S. pneumoniae were cultured and 
adjusted to the appropriate concentration as described above. The bacteria were added to 
the cells to yield a MOI of 2.5 and were then centrifuged at 190 g, 37°C for 5 min. After 1 h 
incubation at 37°C + 5% CO2, the cells were washed 3x with PBS and incubated with 50 
µg/ml gentamycin in RPMI 1640 for 1 h in order to kill extracellular bacteria. Next, the BMMs 
were washed 3x with PBS and then incubated with 0.1% saponin in PBS for 10 min at 37°C 
+ 5% CO2
 in order to lyse the cells. Additionally, the cells were disrupted by pipetting up and 
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down 10 times. 10 µl of the lysate was plated on a blood agar plate and incubated overnight. 
The number of colony-forming units (CFU) was counted the next day reflecting the number of 
internalized pneumococci. 
 
4.6 In vivo pneumonia model 
Mice were anesthetized by intraperitoneal injection of ketamine (80 mg/kg body weight) and 
xylazine (20 mg/kg body weight) and intranasally inoculated with 1 x 106 CFU S. pneumoniae 
serotype 3 (NCTC7978) in 20 µl PBS. 12 h or 48 h after infection, the mice were 
anesthetized again and sacrificed by final blood withdrawal from the vena cava. The blood 
was used for determination of the bacterial load (see below) and then centrifuged at 1500 g 
for 10 min. The serum was collected, divided into aliquots of 50 µl, and stored immediately in 
liquid nitrogen. Tubes were transferred to -80°C fridge for long-term storage.  
The lung was perfused with sterile 0.9% NaCl via the pulmonary artery for 3 min. The lungs 
were lavaged twice with 800 µl PBS containing protease inhibitors (1 tablet per 10 ml PBS). 
CFU were determined from the first lavage (see below). Both lavages were centrifuged at 
2200 rpm for 10 min at 4°C. The supernatant of the first lavage was divided into aliquots of 
150 µl and stored in liquid nitrogen. The supernatant from the second lavage was discarded. 
The cell pellets were combined and used for further analysis (see below). Lung, liver and 
spleen of each mouse was removed and stored at -80°C. 
4.6.1 Measurement of the bacterial burden in the lung and in the blood 
To determine the bacterial number in the BAL and in the blood, serial dilutions were prepared 
from the first lavage or from whole blood directly after the isolation. In case of the BAL, 
dilutions up to 1:104-fold were prepared for the 12 h value and up to 1:105-fold for the 48 h 
value. 10 µl of the BAL (undiluted or the respective dilution) were plated on a Columbia blood 
agar plate. The blood of the infected mice was either used undiluted for CFU determination 
(12 h value) or diluted up to 1:103-fold. : 5 µl (undiluted – 1:103) were plated on a blood agar 
plate. Agar plates were incubated at 37°C + 5% CO2 overnight. CFU were counted the next 
day. 
4.6.2 Measurement of immune cell influx during pneumonia 
The cell pellets from both lavages (see above) were pooled in 1 ml of PBS. Total cell 
numbers were determined with a haemocytometer. Approximately 1x105 cells were applied 
onto a CytoSpin tube (Thermo Scientific) and centrifuged onto a glass slide at 800 rpm for 8 
min. Samples from every mouse were prepared in duplicate. The cells on the glass slide 
were air-dried for at least 20 min, but not longer than 2 days.  
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Cells were then stained with the Pappenheim staining. Phosphate buffer (Waldeck) was 
diluted 1:11 in ddH2O. The glass slides were dipped into May-Grünwalds Eosin-Methylblau 
solution for 4 min. Afterwards, the slides were rinsed in diluted phosphate buffer for 10 times. 
Next, the slides were stained in Giemsa solution (diluted 1:10 in the diluted phosphate buffer) 
for 8 min. After rinsing the slides in dilute phosphate buffer again, they were air-dried. 
The composition of the cell populations from the BAL was visually determined under the 
microscope. Macrophages and PMNs could be clearly distinguished and the relative amount 
per visual field was determined. Two visual fields per glass slide and two glass slides per 
mouse were counted. The average relative amount of macrophages and PMNs was then 
related to the absolute numbers of cell influx. 
4.6.3 RNA-isolation from mouse lungs 
Lungs from infected mice were isolated, cut into pieces, frozen in liquid nitrogen, and then 
stored at -80°C. For RNA isolation, each sample was transferred into 1 ml of Trizol reagent 
and then mechanically homogenized. The suspension was centrifuged at 12,000 g for 10 min 
at 4°C. The supernatant was transferred into a new tube and 200 µl chloroform was added. 
The tubes were vortexed for 15 sec and incubated at room temperature for 2-3 min. 
Afterwards, the samples were centrifuged for 15 min at 12,000g and 4°C. The upper phase 
was carefully transferred into a new tube and 500 µl 2-propanol were added. The tubes were 
vortexed and then centrifuged for 20 min at 12,000 g at 4°C. The supernatant was discarded 
and the RNA pellet was washed/vortexed in 700 µl 70% ethanol. After another centrifugation 
step for 15 min at 12,000 g and 4°C the supernatant was discarded and the pellet was 
resuspended in 100 µl RNase-free H2O. The tube was vortexed until the pellet was dissolved 
and stored at -80°C. Digestion of genomic DNA was performed by using the RNeasy Kit 
(Qiagen) according to protocol. 1 µg RNA was used for the transcription to cDNA (see 
above).  
4.7 Statistical analysis 
Data was analyzed using the GraphPad Prism software, Version 4.02. The distribution of the 
samples was tested for a normal distribution with the D’Agostino and Pearson Omnibus 
Normality Test. Samples that were normally distributed were analysed with the Student’s T 
Test for the comparison of two populations or with ANOVA followed by a Bonferroni post-hoc 
test, when more than two populations were compared. Samples that were not normally 
distributed were analysed with the Mann-Whitney U Test for the comparison of two 
populations, or with the Kruskal-Wallis Test followed by a Dunn’s post-hoc test, when more 
than two populations were compared. The uninfected controls in Fig 14 – 16 were not 
included into the statistical analysis due to insufficient sample sizes. 
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4.8 Reagents and instruments 
Tab. 4: Reagents (in alphabetical order) 
Ammonium chloride Sigma 
Bacto Todd Hewitt Broth BD Biosciences 
Bacto Yeast extract BD Biosciences 
Bafilomycin A Calbiochem 
Biotinylated antibodies BD Biosciences 
Chloroquine Sigma 
Columbia Agar + 5% sheep blood BD Biosciences 
Complete protease inhibitor cocktail tablets Roche 
Cytochalasin D Sigma 
DAPI (4',6-diamidino-2-phenylindole) Sigma 
Dispase BD Biosciences 
DMEM high glucose Gibco 
DMSO Sigma 
DNase Sigma/Serva 
Dynabeads biotin binder Invitrogen 
EDTA Roth 
Erythromycin Sigma 
Ethanol Merck 
FCS PAA 
Gentamycin PAA 
Giemsa Merck 
Glycerol Roth 
HBSS PAA 
HEPES Biochrom 
L-glutamine PAA 
LPS Alexa Biochemicals 
Kanamycin Sigma 
Ketamine 10% WDT 
Lysozyme Merck 
Magnesium chloride Sigma 
MALP2 Alexa Biochemicals 
May-Grünwalds Eosin-Methylblau solution Merck 
MDP Invitrogen 
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mIFNβ PBL interferon source 
 
Pancoll PAN Biotech GmbH 
PBS PAA 
phosphate buffer, pH 7.2 Waldeck 
Penicillin/Streptomycin PAA 
Potassium chloride Merck 
poly dA:dT Sigma 
poly I:C Invitrogen 
Proteinase K Calbiochem 
RNase A Sigma 
RNase H Ambion 
RPMI1640 Gibco 
Saponin Sigma 
Syto®82 Orange Fluorescent Nucleic Acid Stain Invitrogen 
Tris-HCl Sigma 
Xylazine (Rompun) Bayer 
  
 
Tab. 5: Kits 
Transfection  
HiPerFect Qiagen 
Lipofectamine 2000 Invitrogen 
  
RNA/DNA purification  
DNeasy Blood & Tissue Qiagen 
Gene Expression Master Mix Applied Biosystems 
HCRT Applied Biosystems 
Nucleospin II Macherey & Nagel 
PerfectPure RNA Cultured Cell Kit 5Prime 
Taqman gene expression assays Applied Biosystems 
  
ELISA  
Cytokine multiplex assay Bio-Rad 
mIFNβ PBL Biomedical Laboratories 
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ELISA  
mIL-1β eBioscience 
mRANTES RayBiotech Inc. 
 
Tab. 6: antibodies and reagents for FACS 
anti-CD45-FITC BD Biosciences 
anti-pro-SP-C Chemicon 
anti-rabbit-Alexa647 Invitrogen 
FACS washing buffer BD Biosciences 
 
Tab. 7: instrumentation and other (alphabetical order) 
0.2 µM filters BD Biosciences 
ABI 7300 instrument (qPCR) Applied Biosystems 
Cell culture inserts and corresponding plate BD Biosciences 
Cell filter (20 µm) Millipore 
Cell strainers (100 µm, 70 µm, 40 µm) BD Biosciences 
ELISA plate reader STL 
FACS Calibur BD Biosciences 
non-tissue culture treated dishes Optilux BD Biosciences 
Sonicator Sonoplus UW2070 Bandelin 
Thermomixer Eppendorf 
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